Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:dopamine
go back to main search page
Accession:CHEBI:18243 term browser browse the term
Definition:Catechol in which the hydrogen at position 4 is substituted by a 2-aminoethyl group.
Synonyms:related_synonym: 2-(3,4-Dihydroxyphenyl)ethylamine;   3,4-Dihydroxyphenethylamine;   3-Hydroxytyramine;   4-(2-Aminoethyl)-1,2-benzenediol;   4-(2-Aminoethyl)benzene-1,2-diol;   4-(2-aminoethyl)catechol;   4-(2-aminoethyl)pyrocatechol;   Deoxyepinephrine;   Formula=C8H11NO2;   Hydroxytyramin;   InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2;   InChIKey=VYFYYTLLBUKUHU-UHFFFAOYSA-N;   SMILES=NCCc1ccc(O)c(O)c1;   dopamina;   dopaminum
 alt_id: CHEBI:11695;   CHEBI:11930;   CHEBI:14203;   CHEBI:1764;   CHEBI:23886;   CHEBI:43686
 xref: CAS:51-61-6;   DrugBank:DB00988;   Drug_Central:947;   HMDB:HMDB0000073;   KEGG:C03758;   KEGG:D07870;   KNApSAcK:C00001408;   LINCS:LSM-4630
 xref_mesh: MESH:D004298
 xref: MetaCyc:DOPAMINE;   PMID:10629745;   PMID:11149432;   PMID:9422813;   Reaxys:1072822;   Wikipedia:Dopamine
 cyclic_relationship: is_conjugate_base_of CHEBI:59905


show annotations for term's descendants           Sort by:
 
dopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A3galt2 alpha 1,3-galactosyltransferase 2 increases expression EXP Dopamine results in increased expression of A3GALT2 mRNA CTD PMID:21983523 NCBI chr 5:146,933,592...146,945,882
Ensembl chr 5:146,933,592...146,945,880
JBrowse link
G Abl2 ABL proto-oncogene 2, non-receptor tyrosine kinase decreases expression EXP Dopamine results in decreased expression of ABL2 mRNA CTD PMID:21983523 NCBI chr13:74,154,533...74,333,244
Ensembl chr13:74,154,835...74,333,244
JBrowse link
G Actb actin, beta affects expression ISO Dopamine affects the expression of ACTB protein CTD PMID:24675778 NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
JBrowse link
G Actbl2 actin, beta-like 2 decreases expression ISO Dopamine results in decreased expression of ACTBL2 protein CTD PMID:24675778 NCBI chr 2:42,829,413...42,832,160
Ensembl chr 2:42,829,413...42,832,160
JBrowse link
G Actg1 actin, gamma 1 increases expression EXP Dopamine results in increased expression of ACTG1 mRNA CTD PMID:21983523 NCBI chr10:109,518,429...109,521,288
Ensembl chr 3:75,643,054...75,644,954
Ensembl chr10:75,643,054...75,644,954
JBrowse link
G Adam9 ADAM metallopeptidase domain 9 increases expression EXP Dopamine results in increased expression of ADAM9 mRNA CTD PMID:21983523 NCBI chr16:71,810,377...71,887,926
Ensembl chr16:71,810,377...71,887,926
JBrowse link
G Adamts4 ADAM metallopeptidase with thrombospondin type 1 motif, 4 increases expression EXP Dopamine results in increased expression of ADAMTS4 mRNA CTD PMID:21983523 NCBI chr13:89,622,996...89,632,485
Ensembl chr13:89,622,632...89,634,419
JBrowse link
G Adora1 adenosine A1 receptor multiple interactions EXP [N(6)-cyclohexyladenosine binds to and results in increased activity of ADORA1 protein] promotes the reaction [Methamphetamine results in increased secretion of Dopamine] CTD PMID:11043458 NCBI chr13:51,042,111...51,076,913
Ensembl chr13:51,042,248...51,076,852
JBrowse link
G Adra2a adrenoceptor alpha 2A affects binding ISO Dopamine binds to ADRA2A protein CTD PMID:10336518 NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081
JBrowse link
G Adra2c adrenoceptor alpha 2C affects binding ISO Dopamine binds to ADRA2C protein CTD PMID:10336518 NCBI chr14:80,730,307...80,732,010
Ensembl chr14:80,730,307...80,732,010
JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions EXP [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine] CTD PMID:10894789 NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
JBrowse link
G Agt angiotensinogen multiple interactions ISO Clozapine inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Clozapine promotes the reaction [Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]]; Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]; Raclopride inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]] CTD PMID:11549694 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions EXP [[CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline] inhibits the reaction [Cocaine results in increased abundance of and results in increased secretion of Dopamine]; ALDH2 protein affects the reaction [Cocaine results in increased abundance of Dopamine] CTD PMID:20729865 NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
JBrowse link
G Aldoa aldolase, fructose-bisphosphate A increases expression ISO Dopamine results in increased expression of ALDOA protein CTD PMID:24675778 NCBI chr 1:198,228,387...198,233,988
Ensembl chr 1:198,228,387...198,233,588
JBrowse link
G Anxa3 annexin A3 increases expression ISO Dopamine results in increased expression of ANXA3 protein CTD PMID:24675778 NCBI chr14:14,371,921...14,426,503
Ensembl chr14:14,364,008...14,426,437
JBrowse link
G Arg1 arginase 1 decreases expression EXP Dopamine results in decreased expression of ARG1 mRNA; Dopamine results in decreased expression of ARG1 protein CTD PMID:25818600 NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
JBrowse link
G Atp2b2 ATPase plasma membrane Ca2+ transporting 2 decreases expression EXP Dopamine results in decreased expression of ATP2B2 mRNA CTD PMID:21983523 NCBI chr 4:145,704,779...145,948,997
Ensembl chr 4:145,703,046...146,016,325
JBrowse link
G Atp5pd ATP synthase peripheral stalk subunit d increases expression ISO Dopamine results in increased expression of ATP5PD protein CTD PMID:24675778 NCBI chr10:103,967,340...103,972,552
Ensembl chr10:103,967,312...103,972,668
JBrowse link
G B4galt1 beta-1,4-galactosyltransferase 1 increases expression EXP Dopamine results in increased expression of B4GALT1 mRNA CTD PMID:21983523 NCBI chr 5:57,121,768...57,168,610
Ensembl chr 5:57,121,769...57,168,610
JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression ISO Dopamine results in decreased expression of BAX protein CTD PMID:19410601 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbc3 Bcl-2 binding component 3 increases expression ISO [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 protein CTD PMID:19410601 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions
ISO Dopamine results in decreased expression of BCL2 protein
polydatin inhibits the reaction [Dopamine results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [Dopamine results in decreased expression of BCL2 protein]
CTD PMID:17603292, PMID:28980048 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bdnf brain-derived neurotrophic factor increases abundance ISO BDNF gene mutant form results in increased abundance of Dopamine CTD PMID:11421589 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 protein CTD PMID:19410601 NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
JBrowse link
G C1qbp complement C1q binding protein increases expression ISO Dopamine results in increased expression of C1QBP protein CTD PMID:24675778 NCBI chr10:57,613,876...57,618,527
Ensembl chr10:57,613,879...57,618,527
JBrowse link
G Calu calumenin increases expression EXP Dopamine results in increased expression of CALU mRNA CTD PMID:21983523 NCBI chr 4:56,625,611...56,653,112
Ensembl chr 4:56,625,561...56,653,111
JBrowse link
G Caly calcyon neuron-specific vesicular protein decreases secretion ISO CALY protein results in decreased secretion of Dopamine CTD PMID:30753204 NCBI chr 1:212,537,851...212,549,040
Ensembl chr 1:212,537,848...212,549,477
JBrowse link
G Camk2a calcium/calmodulin-dependent protein kinase II alpha multiple interactions EXP [Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]] CTD PMID:19217379 NCBI chr18:56,193,978...56,295,869
Ensembl chr18:56,193,978...56,295,869
JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
increases cleavage
ISO
EXP
[Dopamine co-treated with Zinc deficiency] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Dopamine results in increased activity of and results in increased cleavage of CASP3 protein]; Dopamine results in increased activity of and results in increased cleavage of CASP3 protein; Dopamine results in increased cleavage of and results in increased activity of CASP3 protein; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of CASP3 protein]; resveratrol inhibits the reaction [Dopamine results in increased cleavage of and results in increased activity of CASP3 protein]
Dopamine results in increased activity of CASP3 protein
SH-6 compound promotes the reaction [Dopamine results in increased activity of CASP3 protein]; SH-6 compound promotes the reaction [tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein]]; tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein]
CTD PMID:15198987, PMID:17136323, PMID:17603292, PMID:18194434, PMID:19410601, PMID:22987761, PMID:23377617 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 multiple interactions
increases activity
ISO Acetylcysteine inhibits the reaction [Dopamine results in increased activity of and results in increased cleavage of CASP7 protein]; Dopamine results in increased activity of and results in increased cleavage of CASP7 protein
Dopamine results in increased activity of CASP7 protein
CTD PMID:17136323, PMID:19410601 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Cat catalase multiple interactions
increases expression
ISO
EXP
CAT protein inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in decreased abundance of Dopamine]
Dopamine results in increased expression of CAT mRNA
[Dopamine co-treated with Dicumarol] results in increased expression of CAT mRNA
CTD PMID:11299314, PMID:11435997 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cbx7 chromobox 7 decreases expression EXP Dopamine results in decreased expression of CBX7 mRNA CTD PMID:21983523 NCBI chr 7:121,136,067...121,153,503
Ensembl chr 7:121,136,058...121,153,383
JBrowse link
G Ccl22 C-C motif chemokine ligand 22 decreases expression EXP Dopamine results in decreased expression of CCL22 mRNA CTD PMID:25818600 NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145
JBrowse link
G Cd55 CD55 molecule (Cromer blood group) increases expression EXP Dopamine results in increased expression of CD55 mRNA CTD PMID:21983523 NCBI chr13:47,125,156...47,153,557
Ensembl chr13:47,126,741...47,154,292
JBrowse link
G Cfl1 cofilin 1 increases expression ISO Dopamine results in increased expression of CFL1 protein CTD PMID:24675778 NCBI chr 1:220,869,805...220,873,337
Ensembl chr 1:220,869,805...220,873,337
JBrowse link
G Chrm5 cholinergic receptor, muscarinic 5 decreases secretion
affects secretion
ISO CHRM5 gene mutant form results in decreased secretion of Dopamine
CHRM5 protein affects the secretion of Dopamine
CTD PMID:15213703 NCBI chr 3:103,966,451...104,018,815
Ensembl chr 3:103,966,451...104,018,861
JBrowse link
G Chrna3 cholinergic receptor nicotinic alpha 3 subunit increases secretion EXP CHRNA3 protein results in increased secretion of Dopamine CTD PMID:15542623 NCBI chr 8:59,594,007...59,607,122
Ensembl chr 8:59,592,403...59,607,275
JBrowse link
G Chrna6 cholinergic receptor nicotinic alpha 6 subunit multiple interactions ISO [pozanicline binds to and results in increased activity of [CHRNA6 protein binds to CHRNB2 protein]] which results in increased secretion of Dopamine; Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine] CTD PMID:17227438, PMID:19481067 NCBI chr16:68,860,018...68,866,718
Ensembl chr16:68,860,018...68,866,718
JBrowse link
G Chrnb2 cholinergic receptor nicotinic beta 2 subunit multiple interactions ISO [pozanicline binds to and results in increased activity of [CHRNA6 protein binds to CHRNB2 protein]] which results in increased secretion of Dopamine; Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine] CTD PMID:17227438, PMID:19481067 NCBI chr 2:189,088,570...189,096,785
Ensembl chr 2:189,088,570...189,096,785
JBrowse link
G Chrnb4 cholinergic receptor nicotinic beta 4 subunit increases secretion EXP CHRNB4 protein results in increased secretion of Dopamine CTD PMID:15542623 NCBI chr 8:59,610,489...59,629,073
Ensembl chr 8:59,609,693...59,629,133
JBrowse link
G Ckap4 cytoskeleton-associated protein 4 increases expression EXP Dopamine results in increased expression of CKAP4 mRNA CTD PMID:21983523 NCBI chr 7:24,935,243...24,947,595
Ensembl chr 7:24,939,498...24,947,595
JBrowse link
G Clic1 chloride intracellular channel 1 increases expression EXP Dopamine results in increased expression of CLIC1 mRNA CTD PMID:21983523 NCBI chr20:5,040,314...5,049,166
Ensembl chr20:5,040,337...5,049,166
JBrowse link
G Col12a1 collagen type XII alpha 1 chain increases expression EXP Dopamine results in increased expression of COL12A1 mRNA CTD PMID:21983523 NCBI chr 8:87,042,820...87,150,701
Ensembl chr 8:87,040,799...87,158,368
JBrowse link
G Comt catechol-O-methyltransferase increases methylation
increases metabolic processing
multiple interactions
ISO
EXP
COMT protein results in increased methylation of Dopamine
COMT protein results in increased metabolism of Dopamine
[tolcapone results in decreased activity of COMT protein] promotes the reaction [Clozapine results in increased abundance of Dopamine]; COMT protein affects the reaction [Amphetamine results in increased abundance of Dopamine]
3,4-methylenedioxyethamphetamine inhibits the reaction [COMT protein results in increased methylation of Dopamine]; [entacapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine inhibits the reaction [COMT protein results in increased methylation of Dopamine]
CTD PMID:7566641, PMID:11160877, PMID:11248589, PMID:12898346, PMID:14574438, PMID:15190105, PMID:19462939, PMID:20626558 NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A increases expression EXP Dopamine results in increased expression of CPT1A mRNA; Dopamine results in increased expression of CPT1A protein CTD PMID:8479178 NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP [Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein; Calcium promotes the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; Dizocilpine Maleate inhibits the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; Dopamine binds to and results in increased activity of CREB1 protein; KN 62 inhibits the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; SCH 23390 inhibits the reaction [[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein] CTD PMID:14622123 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
JBrowse link
G Cs citrate synthase increases expression ISO Dopamine results in increased expression of CS protein CTD PMID:24675778 NCBI chr 7:2,752,680...2,778,963
Ensembl chr 7:2,752,680...2,778,963
JBrowse link
G Ctsd cathepsin D increases expression ISO Dopamine results in increased expression of CTSD protein CTD PMID:24675778 NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 increases expression EXP Dopamine results in increased expression of CXCL9 mRNA CTD PMID:25818600 NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
decreases activity
ISO Dopamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
Dopamine results in decreased activity of CYP1A1 protein
CTD PMID:18420780, PMID:18493746 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases activity ISO Dopamine results in decreased activity of CYP1A2 protein CTD PMID:18420780 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Dopamine results in decreased activity of CYP1B1 protein CTD PMID:18420780 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases activity ISO Dopamine results in decreased activity of CYP2C29 protein CTD PMID:18420780 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 decreases activity
increases abundance
multiple interactions
ISO Dopamine results in decreased activity of CYP2D6 protein
CYP2D6 protein results in increased abundance of Dopamine
[CYP2D6 protein results in increased metabolism of Tyramine] which results in increased abundance of Dopamine
CTD PMID:18420780, PMID:26763401 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases activity ISO Dopamine results in decreased activity of CYP2E1 protein CTD PMID:18420780 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Dbh dopamine beta-hydroxylase affects abundance
multiple interactions
ISO
EXP
DBH gene polymorphism affects the abundance of Dopamine
DBH protein affects the reaction [Dopamine binds to DRD2 protein]
CTD PMID:15716360, PMID:16163519 NCBI chr 3:5,709,236...5,731,895
Ensembl chr 3:5,709,236...5,731,898
JBrowse link
G Disc1 DISC1 scaffold protein multiple interactions ISO DISC1 protein modified form results in increased uptake of and affects the metabolism of Dopamine CTD PMID:26754951 NCBI chr19:57,818,838...58,069,992
Ensembl chr19:57,820,260...58,066,152
JBrowse link
G Drd1 dopamine receptor D1 multiple interactions
increases activity
affects localization
ISO
EXP
Dopamine binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Dopamine affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [Dopamine results in increased activity of DRD1 protein]
[alpha-pyrrolidinovalerophenone results in increased secretion of Dopamine] results in increased activity of [DRD1 protein co-treated with DRD2 protein]
[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein; [Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein; Dopamine deficiency inhibits the reaction [SCH 23390 binds to DRD1 protein]; DRD1 protein promotes the reaction [zonisamide affects the secretion of Dopamine]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; SCH 23390 inhibits the reaction [[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]
CTD PMID:12813475, PMID:14622123, PMID:15985612, PMID:19482038, PMID:22292096, PMID:24418703, PMID:31323226 NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
JBrowse link
G Drd2 dopamine receptor D2 multiple interactions
affects response to substance
increases activity
affects binding
ISO
EXP
[Dopamine co-treated with DRD2 protein alternative form] results in increased activity of RHOA protein; [Dopamine co-treated with Raclopride] promotes the reaction [Dopamine binds to DRD2 protein]
[alpha-pyrrolidinovalerophenone results in increased secretion of Dopamine] results in increased activity of [DRD1 protein co-treated with DRD2 protein]
DRD2 protein affects the susceptibility to Dopamine
Dopamine results in increased activity of DRD2 protein
[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine; [Raclopride binds to and results in decreased activity of DRD2 protein] which results in increased abundance of Dopamine; [Remoxipride results in decreased activity of DRD2 protein] inhibits the reaction [Dopamine results in decreased susceptibility to Pilocarpine]; Clozapine promotes the reaction [Dopamine binds to DRD2 protein]; Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]; cypermethrin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; DBH protein affects the reaction [Dopamine binds to DRD2 protein]; decamethrin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of IL10 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of TGFB1 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of VEGFA protein]; DRD2 mutant form inhibits the reaction [Dopamine results in increased expression of TNF protein]; DRD4 protein affects the reaction [Dopamine binds to DRD2 protein]; estradiol 3-benzoate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Ethanol affects the reaction [Dopamine binds to DRD2 protein]; GRK6 protein affects the reaction [Dopamine binds to DRD2 protein]; Haloperidol inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Haloperidol promotes the reaction [Dopamine binds to DRD2 protein]; Olanzapine promotes the reaction [Dopamine binds to DRD2 protein]; Quetiapine Fumarate promotes the reaction [Dopamine binds to DRD2 protein]; Risperidone promotes the reaction [Dopamine binds to DRD2 protein]; Spiperone inhibits the reaction [Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]]; tautomycin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Tea inhibits the reaction [Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]]
Dopamine binds to DRD2 protein alternative form
CTD PMID:8103596, PMID:10936494, PMID:12476322, PMID:15140183, PMID:15341276, PMID:15716360, PMID:16480889, PMID:19046384, PMID:19439595, PMID:20729865, PMID:24418703, PMID:25818600, PMID:27717053 NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
JBrowse link
G Drd3 dopamine receptor D3 increases activity
multiple interactions
EXP
ISO
Dopamine results in increased activity of DRD3 protein
Butaclamol inhibits the reaction [Dopamine results in increased activity of DRD3 protein]; Dopamine binds to and results in increased activity of DRD3 protein
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; [Raclopride binds to and results in decreased activity of DRD3 protein] which results in increased abundance of Dopamine; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]]
CTD PMID:15341276, PMID:19046384, PMID:19217379, PMID:31323226 NCBI chr11:61,819,102...61,883,223
Ensembl chr11:61,822,077...61,874,327
JBrowse link
G Drd4 dopamine receptor D4 multiple interactions EXP
ISO
DRD4 protein affects the reaction [Dopamine binds to DRD2 protein]
Clozapine inhibits the reaction [Dopamine results in increased activity of DRD4 protein]; Dopamine binds to and results in increased activity of DRD4 protein
CTD PMID:15716360, PMID:31323226 NCBI chr 1:214,278,296...214,282,818
Ensembl chr 1:214,278,296...214,281,483
JBrowse link
G Drd5 dopamine receptor D5 increases expression EXP Dopamine results in increased expression of DRD5 mRNA CTD PMID:18522901 NCBI chr14:77,220,579...77,222,006
Ensembl chr14:77,220,579...77,222,006
JBrowse link
G Ecm2 extracellular matrix protein 2 decreases expression EXP Dopamine results in decreased expression of ECM2 mRNA CTD PMID:21983523 NCBI chr17:15,533,760...15,566,403
Ensembl chr17:15,533,972...15,566,332
JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 increases expression ISO Dopamine results in increased expression of EEF1A1 protein CTD PMID:24675778 NCBI chr 8:85,838,594...85,841,816
Ensembl chr 8:85,838,869...85,840,818
JBrowse link
G Efhd2 EF-hand domain family, member D2 multiple interactions
decreases secretion
ISO [EFHD2 gene mutant form affects the susceptibility to Ethanol] which results in increased secretion of Dopamine
EFHD2 gene mutant form results in decreased secretion of Dopamine
CTD PMID:28397836 NCBI chr 5:160,407,777...160,423,811
Ensembl chr 5:160,407,778...160,423,811
JBrowse link
G En1 engrailed homeobox 1 multiple interactions ISO [EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in increased abundance of Dopamine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]] CTD PMID:21892157 NCBI chr13:36,532,758...36,537,888
Ensembl chr13:36,532,758...36,537,093
JBrowse link
G En2 engrailed homeobox 2 multiple interactions ISO [EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in increased abundance of Dopamine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]] CTD PMID:21892157 NCBI chr 4:438,668...444,508
Ensembl chr 4:438,668...444,501
JBrowse link
G Eng endoglin decreases expression EXP Dopamine results in decreased expression of ENG mRNA CTD PMID:21983523 NCBI chr 3:11,679,530...11,717,486
Ensembl chr 3:11,679,530...11,717,485
JBrowse link
G Enpp3 ectonucleotide pyrophosphatase/phosphodiesterase 3 increases expression EXP Dopamine results in increased expression of ENPP3 mRNA CTD PMID:21983523 NCBI chr 1:21,613,148...21,684,483
Ensembl chr 1:21,613,148...21,684,480
JBrowse link
G Erp29 endoplasmic reticulum protein 29 increases expression EXP Dopamine results in increased expression of ERP29 mRNA CTD PMID:21983523 NCBI chr12:40,619,377...40,625,884
Ensembl chr12:40,619,377...40,625,883
JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions ISO Dopamine promotes the reaction [TNF protein results in increased expression of F3 mRNA] CTD PMID:20118172 NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
JBrowse link
G Fn1 fibronectin 1 increases expression EXP Dopamine results in increased expression of FN1 mRNA CTD PMID:21983523 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
ISO
EXP
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein; bisindolylmaleimide I inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]
Dopamine results in increased expression of FOS mRNA; Dopamine results in increased expression of FOS protein
CTD PMID:10700011, PMID:12112414, PMID:19217379 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases activity
decreases activity
multiple interactions
EXP Dopamine results in increased activity of G6PD protein
Dopamine results in decreased activity of G6PD protein
Atenolol inhibits the reaction [Dopamine results in increased activity of G6PD protein]
CTD PMID:1978808, PMID:26820767 NCBI chr  X:156,274,800...156,293,935
Ensembl chr  X:156,274,800...156,293,926
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase increases expression ISO Dopamine results in increased expression of GAPDH protein CTD PMID:24675778 NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
JBrowse link
G Gch1 GTP cyclohydrolase 1 increases abundance EXP GCH1 protein results in increased abundance of Dopamine CTD PMID:15929554 NCBI chr15:23,935,011...23,968,971
Ensembl chr15:23,934,585...23,969,011
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO Dopamine promotes the reaction [Zinc deficiency results in increased cleavage of GCLC protein] CTD PMID:23377617 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO [GCLM gene mutant form results in increased susceptibility to Paraquat] which results in decreased abundance of Dopamine CTD PMID:23704229 NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
JBrowse link
G Gdnf glial cell derived neurotrophic factor multiple interactions
increases metabolic processing
ISO
EXP
GDNF protein inhibits the reaction [Oxidopamine results in decreased secretion of Dopamine]
GDNF protein results in increased metabolism of Dopamine
CTD PMID:12213621, PMID:15269253 NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
JBrowse link
G Ghrl ghrelin and obestatin prepropeptide decreases export EXP GHRL protein results in decreased export of Dopamine CTD PMID:20553917 NCBI chr 4:145,674,157...145,678,066
Ensembl chr 4:145,674,157...145,678,066
JBrowse link
G Gnrh1 gonadotropin releasing hormone 1 multiple interactions EXP Dopamine affects the reaction [manganese chloride results in increased secretion of GNRH1 protein] CTD PMID:18603625 NCBI chr15:44,441,856...44,446,064
Ensembl chr15:44,442,555...44,442,875
Ensembl chr15:44,442,555...44,442,875
JBrowse link
G Gria1 glutamate ionotropic receptor AMPA type subunit 1 increases localization EXP Dopamine results in increased localization of GRIA1 protein CTD PMID:19674091 NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200
JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 increases localization EXP Dopamine results in increased localization of GRIA2 protein CTD PMID:19674091 NCBI chr 2:179,584,302...179,704,629
Ensembl chr 2:179,584,308...179,704,629
JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 multiple interactions EXP [Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein] CTD PMID:14622123 NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
JBrowse link
G Grk6 G protein-coupled receptor kinase 6 multiple interactions EXP GRK6 protein affects the reaction [Dopamine binds to DRD2 protein] CTD PMID:15716360 NCBI chr17:9,705,917...9,721,921
Ensembl chr17:9,703,453...9,721,574
JBrowse link
G Grm5 glutamate metabotropic receptor 5 multiple interactions EXP [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in decreased abundance of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Veratridine results in increased secretion of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] which results in decreased secretion of Dopamine CTD PMID:12907309 NCBI chr 1:151,207,846...151,785,038
Ensembl chr 1:151,439,409...151,783,392
JBrowse link
G Gsr glutathione-disulfide reductase decreases activity EXP Dopamine results in decreased activity of GSR protein CTD PMID:26820767 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 decreases activity ISO Dopamine analog results in decreased activity of GSTA1 protein CTD PMID:8131222 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Gstm1 glutathione S-transferase mu 1 decreases activity ISO Dopamine analog results in decreased activity of GSTM1 protein CTD PMID:8131222 NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
JBrowse link
G Gstp1 glutathione S-transferase pi 1 decreases activity ISO Dopamine analog results in decreased activity of GSTP1 protein CTD PMID:8131222 NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
JBrowse link
G H1f5 H1.5 linker histone, cluster member increases expression ISO Dopamine results in increased expression of H1-5 protein CTD PMID:24675778 NCBI chr17:44,766,313...44,766,981
Ensembl chr17:44,766,313...44,766,981
JBrowse link
G Hcrtr1 hypocretin receptor 1 multiple interactions EXP [1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea binds to and results in decreased activity of HCRTR1 protein] inhibits the reaction [Amphetamine results in increased secretion of Dopamine] CTD PMID:19737591 NCBI chr 5:148,346,029...148,355,404
Ensembl chr 5:148,346,031...148,355,406
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression
multiple interactions
decreases expression
ISO
EXP
[Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 protein; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 protein; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of TP53 protein; Dopamine results in increased expression of HIF1A protein
Clodronic Acid inhibits the reaction [Dopamine results in decreased expression of HIF1A protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of HIF1A protein]; zoledronic acid inhibits the reaction [Dopamine results in decreased expression of HIF1A protein]
[Dopamine results in increased expression of HIF1A protein] which results in increased expression of and results in increased phosphorylation of TP53 protein; Acetylcysteine inhibits the reaction [Dopamine results in increased expression of HIF1A protein]
CTD PMID:19410601, PMID:25818600 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 decreases expression EXP Dopamine results in decreased expression of HMGCS2 mRNA CTD PMID:21983523 NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions
EXP
ISO
[Dopamine results in increased expression of HMOX1 mRNA] which results in increased expression of SOD2 mRNA; Dopamine results in increased expression of HMOX1 mRNA
[SNCA protein co-treated with Dopamine] results in increased expression of HMOX1 protein; [SNCA protein co-treated with Paraquat co-treated with Dopamine] results in increased expression of HMOX1 protein; HMOX1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased abundance of Dopamine]
CTD PMID:10942521, PMID:18799798, PMID:21735318 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hrh1 histamine receptor H 1 multiple interactions EXP [1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog binds to and results in increased activity of HRH1 protein] promotes the reaction [TH protein results in increased chemical synthesis of Dopamine] CTD PMID:10661506 NCBI chr 4:146,374,596...146,458,148
Ensembl chr 4:146,455,332...146,457,074
JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 increases expression ISO Dopamine results in increased expression of HSP90AB1 protein CTD PMID:24675778 NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
JBrowse link
G Hsp90b1 heat shock protein 90 beta family member 1 increases expression ISO Dopamine results in increased expression of HSP90B1 protein CTD PMID:24675778 NCBI chr 7:27,226,570...27,240,533
Ensembl chr 7:27,226,569...27,240,533
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression ISO Dopamine results in increased expression of HSPA5 protein CTD PMID:24675778 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Hspa9 heat shock protein family A (Hsp70) member 9 increases expression ISO Dopamine results in increased expression of HSPA9 protein CTD PMID:24675778 NCBI chr18:27,731,072...27,749,235
Ensembl chr18:27,731,072...27,749,235
JBrowse link
G Htr2a 5-hydroxytryptamine receptor 2A multiple interactions EXP [4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine; Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]] CTD PMID:10773215 NCBI chr15:56,666,152...56,732,469
Ensembl chr15:56,666,012...56,735,382
JBrowse link
G Htr2c 5-hydroxytryptamine receptor 2C multiple interactions ISO HTR2C protein affects the reaction [Cocaine results in increased abundance of Dopamine] CTD PMID:12427861 NCBI chr  X:118,084,520...118,318,040
Ensembl chr  X:118,084,890...118,318,039
JBrowse link
G Htr3a 5-hydroxytryptamine receptor 3A multiple interactions ISO Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3A protein]; Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3B protein] CTD PMID:17360702 NCBI chr 8:53,211,436...53,223,878
Ensembl chr 8:53,211,438...53,223,804
JBrowse link
G Htr3b 5-hydroxytryptamine receptor 3B multiple interactions ISO Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3B protein] CTD PMID:17360702 NCBI chr 8:53,247,881...53,278,170
Ensembl chr 8:53,248,705...53,277,859
JBrowse link
G Il10 interleukin 10 decreases expression
multiple interactions
EXP Dopamine results in decreased expression of IL10 mRNA; Dopamine results in decreased expression of IL10 protein
DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of IL10 protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of IL10 protein]
CTD PMID:25818600 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Ins2 insulin 2 multiple interactions
increases secretion
increases expression
ISO Dopamine promotes the reaction [Metoclopramide results in increased expression of INS protein]
Dopamine results in increased secretion of INS protein
Dopamine results in increased expression of INS protein
CTD PMID:18645345 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases phosphorylation
multiple interactions
ISO Dopamine results in increased phosphorylation of JUN protein
PRKN protein inhibits the reaction [Dopamine results in increased phosphorylation of JUN protein]
CTD PMID:15198987 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Kcna1 potassium voltage-gated channel subfamily A member 1 multiple interactions EXP KCNA1 protein affects the reaction [Amphetamine results in increased secretion of Dopamine] CTD PMID:12700677 NCBI chr 4:159,190,781...159,192,526
Ensembl chr 4:159,190,804...159,192,526
JBrowse link
G Kcnj6 potassium inwardly-rectifying channel, subfamily J, member 6 decreases abundance ISO KCNJ6 gene mutant form results in decreased abundance of Dopamine CTD PMID:15256069 NCBI chr11:35,011,007...35,262,362
Ensembl chr11:35,024,196...35,099,383
JBrowse link
G Kdelr3 KDEL endoplasmic reticulum protein retention receptor 3 increases expression EXP Dopamine results in increased expression of KDELR3 mRNA CTD PMID:21983523 NCBI chr 7:120,749,680...120,760,163
Ensembl chr 7:120,749,752...120,760,160
JBrowse link
G Kpna2 karyopherin subunit alpha 2 increases expression EXP Dopamine results in increased expression of KPNA2 mRNA CTD PMID:21983523 NCBI chr10:95,200,029...95,212,111
Ensembl chr10:95,200,030...95,212,111
JBrowse link
G Lgmn legumain increases expression EXP Dopamine results in increased expression of LGMN mRNA CTD PMID:21983523 NCBI chr 6:126,282,246...126,308,207
Ensembl chr 6:126,282,233...126,320,726
JBrowse link
G Litaf lipopolysaccharide-induced TNF factor increases expression EXP Dopamine results in increased expression of LITAF mRNA CTD PMID:21983523 NCBI chr10:4,753,546...4,763,272
Ensembl chr10:4,719,713...4,763,510
JBrowse link
G Lmna lamin A/C increases expression ISO Dopamine results in increased expression of LMNA protein CTD PMID:24675778 NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
JBrowse link
G Loxl2 lysyl oxidase-like 2 increases expression EXP Dopamine results in increased expression of LOXL2 mRNA CTD PMID:21983523 NCBI chr15:51,276,022...51,365,238
Ensembl chr15:51,303,909...51,365,234
JBrowse link
G Lrat lecithin retinol acyltransferase increases expression EXP Dopamine results in increased expression of LRAT mRNA CTD PMID:21983523 NCBI chr 2:181,896,304...181,905,366
Ensembl chr 2:181,896,305...181,905,300
JBrowse link
G Lrrk2 leucine-rich repeat kinase 2 multiple interactions ISO LRRK2 mutant form results in increased susceptibility to [Dopamine co-treated with SLC6A3 protein] CTD PMID:23628791 NCBI chr 7:132,857,311...133,018,549
Ensembl chr 7:132,857,628...133,018,584
JBrowse link
G Maoa monoamine oxidase A increases abundance
decreases amination
multiple interactions
ISO MAOA mutant form results in increased abundance of Dopamine
MAOA protein results in decreased amination of Dopamine
3,4-Methylenedioxyamphetamine inhibits the reaction [MAOA protein results in decreased amination of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [MAOA protein results in decreased amination of Dopamine]
CTD PMID:11834493, PMID:26721607 NCBI chr  X:6,554,698...6,620,722
Ensembl chr  X:6,554,698...6,620,722
JBrowse link
G Maob monoamine oxidase B multiple interactions
increases degradation
decreases amination
EXP
ISO
[Ro 16-6491 results in decreased activity of MAOB protein] which results in decreased susceptibility to Dopamine; [Selegiline results in decreased activity of MAOB protein] which results in increased abundance of Dopamine
MAOB protein results in increased degradation of Dopamine
1-(8-bromobenzo(1,2-b;4,5-b')difuran-4-yl)-2-aminopropane inhibits the reaction [MAOB protein results in increased degradation of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [MAOB protein results in decreased amination of Dopamine]; Selegiline inhibits the reaction [MAOB protein results in decreased amination of Dopamine]; Selegiline inhibits the reaction [MAOB protein results in increased degradation of Dopamine]
CTD PMID:16012872, PMID:20875051, PMID:26721607, PMID:30036687 NCBI chr  X:6,430,694...6,533,520
Ensembl chr  X:6,430,594...6,533,534
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO
EXP
Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein]
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]
CTD PMID:16760913, PMID:18977218, PMID:19217379 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO
EXP
Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein]
DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]]
CTD PMID:16760913, PMID:18977218, PMID:19217379 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases phosphorylation
ISO Acetylcysteine inhibits the reaction [Dopamine results in increased phosphorylation of MAPK8 protein]; Glutathione inhibits the reaction [Dopamine results in increased phosphorylation of MAPK8 protein] CTD PMID:17481858 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapt microtubule-associated protein tau multiple interactions ISO Dopamine metabolite promotes the reaction [MAPT protein binds to MAPT protein]; Dopamine promotes the reaction [MAPT protein binds to MAPT protein] CTD PMID:16180106 NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
JBrowse link
G Marcks myristoylated alanine rich protein kinase C substrate increases expression ISO Dopamine results in increased expression of MARCKS protein CTD PMID:24675778 NCBI chr20:42,966,140...42,971,838
Ensembl chr20:42,966,140...42,971,838
JBrowse link
G Mrc1 mannose receptor, C type 1 decreases expression EXP Dopamine results in decreased expression of MRC1 mRNA; Dopamine results in decreased expression of MRC1 protein CTD PMID:25818600 NCBI chr17:81,352,700...81,433,743
Ensembl chr17:81,352,700...81,433,743
JBrowse link
G Mt1 metallothionein 1 multiple interactions ISO [MT1 co-treated with Dopamine] results in decreased abundance of semiquinone radicals; [MT1 gene mutant form co-treated with MT2 gene mutant form co-treated with Mercuric Chloride] results in decreased abundance of Dopamine CTD PMID:17910954, PMID:18226494 NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
JBrowse link
G Mt2A metallothionein 2A multiple interactions ISO [MT1 gene mutant form co-treated with MT2 gene mutant form co-treated with Mercuric Chloride] results in decreased abundance of Dopamine CTD PMID:18226494 NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation ISO Dopamine results in decreased phosphorylation of MTOR protein CTD PMID:19410601 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase multiple interactions
increases activity
ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dopamine results in increased activity of MTR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dopamine results in increased activity of MTR protein]; Ethanol promotes the reaction [Dopamine results in increased activity of MTR protein]; wortmannin inhibits the reaction [Dopamine results in increased activity of MTR protein] CTD PMID:14745455 NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
JBrowse link
G Myct1 myc target 1 decreases expression EXP Dopamine results in decreased expression of MYCT1 mRNA CTD PMID:21983523 NCBI chr 1:42,121,572...42,132,131
Ensembl chr 1:42,121,636...42,131,547
JBrowse link
G Ncl nucleolin increases expression ISO Dopamine results in increased expression of NCL protein CTD PMID:24675778 NCBI chr 9:93,369,119...93,377,643
Ensembl chr 9:93,368,932...93,377,643
JBrowse link
G Ndufs1 NADH:ubiquinone oxidoreductase core subunit S1 multiple interactions ISO NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]] CTD PMID:21892157 NCBI chr 9:69,919,863...69,953,182
Ensembl chr 9:69,919,867...69,953,182
JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 multiple interactions ISO NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Dopamine]; Paclitaxel inhibits the reaction [NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Dopamine]] CTD PMID:21383081 NCBI chr 2:46,372,488...46,476,162
Ensembl chr 2:46,372,518...46,476,203
JBrowse link
G Nfkbiz NFKB inhibitor zeta increases expression EXP Dopamine results in increased expression of NFKBIZ mRNA CTD PMID:21983523 NCBI chr11:47,243,342...47,271,487
Ensembl chr11:47,243,342...47,271,487
JBrowse link
G Nos1 nitric oxide synthase 1 multiple interactions ISO NOS1 protein affects the reaction [Methamphetamine results in decreased abundance of Dopamine] CTD PMID:11085313, PMID:20575850 NCBI chr12:44,214,949...44,405,530
Ensembl chr12:44,213,943...44,520,341
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression
ISO
EXP
Atenolol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
Dopamine results in increased expression of NOS2 mRNA; Dopamine results in increased expression of NOS2 protein
CTD PMID:19439816, PMID:25818600 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nppc natriuretic peptide C multiple interactions EXP NPPC protein inhibits the reaction [Cocaine results in increased abundance of Dopamine] CTD PMID:11860464 NCBI chr 9:93,731,436...93,735,636
Ensembl chr 9:93,731,436...93,735,636
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 increases abundance
multiple interactions
ISO NR3C1 protein results in increased abundance of Dopamine
[RU 43044 binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]
CTD PMID:11226678, PMID:18925659 NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
JBrowse link
G Nrip3 nuclear receptor interacting protein 3 increases expression EXP Dopamine results in increased expression of NRIP3 mRNA CTD PMID:21983523 NCBI chr 1:174,385,424...174,411,141
Ensembl chr 1:174,385,424...174,411,141
JBrowse link
G Ntf3 neurotrophin 3 increases expression EXP Dopamine results in increased expression of NTF3 mRNA; Dopamine results in increased expression of NTF3 protein CTD PMID:19854260 NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886
JBrowse link
G Omd osteomodulin decreases expression EXP Dopamine results in decreased expression of OMD mRNA CTD PMID:21983523 NCBI chr17:15,476,100...15,484,324
Ensembl chr17:15,475,710...15,484,269
JBrowse link
G Oprk1 opioid receptor, kappa 1 multiple interactions EXP [U 69593 binds to and results in increased activity of OPRK1 protein] inhibits the reaction [Cocaine affects the abundance of Dopamine] CTD PMID:11113311 NCBI chr 5:13,742,655...13,760,460
Ensembl chr 5:13,744,658...13,760,305
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO Dopamine promotes the reaction [Zinc deficiency results in increased cleavage of PARP1 protein]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; resveratrol inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; Zinc deficiency promotes the reaction [Dopamine results in increased cleavage of PARP1 protein]
[PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of Dopamine
CTD PMID:10318960, PMID:15198987, PMID:17603292, PMID:19410601, PMID:22987761, PMID:23377617 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pcmt1 protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 multiple interactions
decreases expression
ISO 1,3-dimethylthiourea inhibits the reaction [Dopamine results in decreased expression of PCMT1 mRNA]; Acetylcysteine inhibits the reaction [Dopamine results in decreased expression of PCMT1 mRNA]; Acetylcysteine inhibits the reaction [Dopamine results in decreased expression of PCMT1 protein]
Dopamine results in decreased expression of PCMT1 mRNA; Dopamine results in decreased expression of PCMT1 protein
CTD PMID:24631677 NCBI chr 1:1,734,863...1,767,759
Ensembl chr 1:1,736,276...1,767,618
JBrowse link
G Pdia3 protein disulfide isomerase family A, member 3 decreases expression ISO Dopamine results in decreased expression of PDIA3 protein CTD PMID:24675778 NCBI chr 3:113,376,983...113,400,707
Ensembl chr 3:113,376,983...113,400,707
JBrowse link
G Pdia6 protein disulfide isomerase family A, member 6 increases expression EXP Dopamine results in increased expression of PDIA6 mRNA CTD PMID:21983523 NCBI chr 6:42,568,269...42,585,654
Ensembl chr 6:42,568,220...42,585,652
JBrowse link
G Pgd phosphogluconate dehydrogenase decreases activity EXP Dopamine results in decreased activity of PGD protein CTD PMID:26820767 NCBI chr 5:165,966,128...165,982,327 JBrowse link
G Pgk1 phosphoglycerate kinase 1 decreases expression EXP Dopamine results in decreased expression of PGK1 mRNA CTD PMID:21983523 NCBI chr  X:77,263,399...77,279,373
Ensembl chr  X:77,263,359...77,279,367
JBrowse link
G Phb prohibitin increases expression ISO Dopamine results in increased expression of PHB protein CTD PMID:24675778 NCBI chr10:83,476,107...83,488,878
Ensembl chr10:83,476,107...83,488,878
JBrowse link
G Pink1 PTEN induced kinase 1 multiple interactions
affects abundance
ISO [PINK1 mutant form results in increased susceptibility to Paraquat] which results in decreased abundance of Dopamine; Paraquat affects the reaction [PINK1 protein affects the abundance of Dopamine] CTD PMID:22043175 NCBI chr 5:156,677,146...156,689,258
Ensembl chr 5:156,677,146...156,689,415
JBrowse link
G Pkm pyruvate kinase M1/2 increases expression ISO Dopamine results in increased expression of PKM protein CTD PMID:24675778 NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
JBrowse link
G Pld3 phospholipase D family, member 3 affects expression ISO Dopamine affects the expression of PLD3 protein CTD PMID:24675778 NCBI chr 1:84,339,269...84,361,686
Ensembl chr 1:84,339,261...84,353,725
JBrowse link
G Plp2 proteolipid protein 2 increases expression EXP Dopamine results in increased expression of PLP2 mRNA CTD PMID:21983523 NCBI chr  X:15,679,254...15,682,653
Ensembl chr  X:15,679,254...15,682,652
JBrowse link
G Pomc proopiomelanocortin multiple interactions ISO POMC protein affects the reaction [Nicotine results in increased abundance of Dopamine] CTD PMID:15689546 NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
JBrowse link
G Potef POTE ankyrin domain family, member F increases expression ISO Dopamine results in increased expression of POTEF protein CTD PMID:24675778 NCBI chr18:24,780,521...24,783,147
Ensembl chr 3:75,643,054...75,644,954
JBrowse link
G Prdx3 peroxiredoxin 3 increases expression ISO Dopamine results in increased expression of PRDX3 protein CTD PMID:24675778 NCBI chr 1:282,238,774...282,251,193
Ensembl chr 1:282,238,773...282,251,257
JBrowse link
G Prkcd protein kinase C, delta multiple interactions ISO [rottlerin results in decreased activity of PRKCD protein] inhibits the reaction [Methamphetamine results in increased metabolism of Dopamine]; PRKCD protein affects the reaction [Methamphetamine results in increased metabolism of Dopamine] CTD PMID:22512859 NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase multiple interactions
increases expression
ISO PRKN protein inhibits the reaction [Dopamine results in increased abundance of Reactive Oxygen Species]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of CASP3 protein]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; PRKN protein inhibits the reaction [Dopamine results in increased phosphorylation of JUN protein]
PRKN mutant form results in increased abundance of and results in increased metabolism of Dopamine; PRKN protein affects the abundance of and affects the metabolism of Dopamine; PRKN protein promotes the reaction [Amphetamine results in increased abundance of Dopamine]
Dopamine results in increased expression of PRKN mRNA
CTD PMID:12915482, PMID:15198987, PMID:15993444, PMID:16987221 NCBI chr 1:48,880,015...50,069,998 JBrowse link
G Prl prolactin multiple interactions
decreases secretion
decreases expression
ISO
EXP
Domperidone inhibits the reaction [Dopamine results in decreased expression of PRL protein]
Haloperidol inhibits the reaction [Dopamine results in decreased secretion of PRL protein]; Risperidone inhibits the reaction [Dopamine results in decreased secretion of PRL protein]
CTD PMID:1380082, PMID:8532072 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
JBrowse link
G Pros1 protein S increases expression EXP Dopamine results in increased expression of PROS1 mRNA CTD PMID:21983523 NCBI chr 7:1,206,648...1,288,140
Ensembl chr 7:1,206,648...1,288,134
JBrowse link
G Ptrh1 peptidyl-tRNA hydrolase 1 homolog increases expression EXP Dopamine results in increased expression of PTRH1 mRNA CTD PMID:21983523 NCBI chr 3:11,811,303...11,817,007
Ensembl chr 3:11,811,962...11,825,640
JBrowse link
G Rack1 receptor for activated C kinase 1 increases expression ISO Dopamine results in increased expression of RACK1 protein CTD PMID:24675778 NCBI chr10:34,149,717...34,155,198
Ensembl chr10:34,149,717...34,155,198
Ensembl chr12:34,149,717...34,155,198
JBrowse link
G Ran RAN, member RAS oncogene family increases expression EXP Dopamine results in increased expression of RAN mRNA CTD PMID:21983523 NCBI chr12:31,319,556...31,324,105
Ensembl chr12:31,320,624...31,323,810
JBrowse link
G Rangap1 RAN GTPase activating protein 1 increases expression EXP Dopamine results in increased expression of RANGAP1 mRNA CTD PMID:21983523 NCBI chr 7:122,939,266...122,967,178
Ensembl chr 7:122,940,376...122,967,178
JBrowse link
G Rgs3 regulator of G-protein signaling 3 multiple interactions ISO RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:18977218 NCBI chr 5:78,429,017...78,567,281
Ensembl chr 5:78,428,669...78,567,288
JBrowse link
G Rhoa ras homolog family member A multiple interactions ISO [Dopamine co-treated with DRD2 protein alternative form] results in increased activity of RHOA protein CTD PMID:27717053 NCBI chr 8:117,082,440...117,116,244
Ensembl chr 8:117,106,576...117,116,167
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO Dopamine results in decreased phosphorylation of RPS6KB1 protein CTD PMID:19410601 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Rpsa ribosomal protein SA increases expression ISO Dopamine results in increased expression of RPSA protein CTD PMID:24675778 NCBI chr 8:128,806,053...128,809,987
Ensembl chr 8:128,806,129...128,809,986
JBrowse link
G Ruvbl1 RuvB-like AAA ATPase 1 increases expression ISO Dopamine results in increased expression of RUVBL1 protein CTD PMID:24675778 NCBI chr 4:120,411,917...120,447,458
Ensembl chr 4:120,411,991...120,447,455
JBrowse link
G S100a11 S100 calcium binding protein A11 increases expression EXP Dopamine results in increased expression of S100A11 mRNA CTD PMID:21983523 NCBI chr 2:193,863,185...193,868,646
Ensembl chr 2:193,866,951...193,868,502
JBrowse link
G S100a4 S100 calcium-binding protein A4 increases expression EXP Dopamine results in increased expression of S100A4 mRNA CTD PMID:21983523 NCBI chr 2:189,997,278...189,999,587
Ensembl chr 2:189,997,129...189,999,604
JBrowse link
G Sct secretin increases metabolic processing ISO SCT protein results in increased metabolism of Dopamine CTD PMID:16168596 NCBI chr 1:214,264,865...214,277,437
Ensembl chr 1:214,264,754...214,265,668
JBrowse link
G Septin9 septin 9 decreases expression ISO Dopamine results in decreased expression of SEPTIN9 protein CTD PMID:24675778 NCBI chr10:106,208,308...106,340,747
Ensembl chr10:106,264,434...106,348,490
JBrowse link
G Shmt2 serine hydroxymethyltransferase 2 increases expression ISO Dopamine results in increased expression of SHMT2 protein CTD PMID:24675778 NCBI chr 7:70,824,718...70,829,822
Ensembl chr 7:70,824,715...70,829,815
JBrowse link
G Slc18a1 solute carrier family 18 member A1 multiple interactions ISO Dopamine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin] CTD PMID:8245983 NCBI chr16:22,358,646...22,395,183
Ensembl chr16:22,361,998...22,395,183
JBrowse link
G Slc18a2 solute carrier family 18 member A2 multiple interactions
increases uptake
decreases activity
affects binding
decreases abundance
ISO
EXP
Heptachlor Epoxide inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; para-methyl-4-methylaminorex inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; Reserpine inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]
DDT inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; Dichlorodiphenyldichloroethane inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; SLC18A2 protein affects the transport of and affects the abundance of Dopamine
Dopamine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]
Dopamine results in decreased activity of SLC18A2 protein
Dopamine binds to SLC18A2 protein
SLC18A2 results in decreased abundance of Dopamine
CTD PMID:1438304, PMID:7912402, PMID:10499361, PMID:15475732, PMID:18533268, PMID:19409267, PMID:27287315, PMID:29908239 NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148
JBrowse link
G Slc22a1 solute carrier family 22 member 1 multiple interactions EXP Dopamine affects the reaction [SLC22A1 protein results in increased uptake of Tetraethylammonium] CTD PMID:12440152 NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
JBrowse link
G Slc22a16 solute carrier family 22 member 16 multiple interactions ISO Dopamine inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] CTD PMID:15963465 NCBI chr20:45,658,398...45,669,192 JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions EXP Dopamine affects the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] CTD PMID:12440152 NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
JBrowse link
G Slc22a3 solute carrier family 22 member 3 increases uptake
multiple interactions
ISO
EXP
SLC22A3 protein results in increased uptake of Dopamine
Dopamine affects the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]; Dopamine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Dopamine inhibits the reaction [SLC22A3 protein results in increased uptake of Dopamine]
CTD PMID:9830022, PMID:20858707 NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
JBrowse link
G Slc25a14 solute carrier family 25 member 14 multiple interactions
decreases response to substance
increases expression
ISO Dactinomycin inhibits the reaction [Dopamine results in increased expression of SLC25A14 mRNA]; SLC25A14 protein inhibits the reaction [Dopamine results in increased abundance of Superoxides]
SLC25A14 protein results in decreased susceptibility to Dopamine
CTD PMID:20600837 NCBI chr  X:135,470,855...135,509,223
Ensembl chr  X:135,470,915...135,509,221
JBrowse link
G Slc25a5 solute carrier family 25 member 5 increases expression ISO Dopamine results in increased expression of SLC25A5 protein CTD PMID:24675778 NCBI chr  X:123,404,570...123,407,637
Ensembl chr  X:123,404,518...123,407,645
JBrowse link
G Slc25a6 solute carrier family 25 member 6 increases expression ISO Dopamine results in increased expression of SLC25A6 protein CTD PMID:24675778 NCBI chr18:70,959,872...70,961,040
Ensembl chr18:70,959,887...70,960,786
JBrowse link
G Slc29a4 solute carrier family 29 member 4 increases uptake ISO SLC29A4 protein results in increased uptake of Dopamine CTD PMID:20858707 NCBI chr12:13,914,114...13,924,511
Ensembl chr12:13,914,114...13,924,531
JBrowse link
G Slc2a4 solute carrier family 2 member 4 decreases expression EXP Dopamine results in decreased expression of SLC2A4 mRNA CTD PMID:21983523 NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
JBrowse link
G Slc39a11 solute carrier family 39, member 11 increases expression EXP Dopamine results in increased expression of SLC39A11 mRNA CTD PMID:21983523 NCBI chr10:101,754,842...102,169,100
Ensembl chr10:101,754,830...102,084,035
JBrowse link
G Slc41a2 solute carrier family 41 member 2 increases expression EXP Dopamine results in increased expression of SLC41A2 mRNA CTD PMID:21983523 NCBI chr 7:26,522,314...26,607,861
Ensembl chr 7:26,522,314...26,607,861
JBrowse link
G Slc6a2 solute carrier family 6 member 2 multiple interactions
increases uptake
ISO Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]
SLC6A2 protein results in increased uptake of Dopamine
CTD PMID:17234900, PMID:20626558 NCBI chr19:15,391,682...15,431,274
Ensembl chr19:15,391,581...15,431,274
JBrowse link
G Slc6a3 solute carrier family 6 member 3 multiple interactions
affects uptake
increases import
decreases import
increases response to substance
increases uptake
affects localization
affects export
affects abundance
increases transport
increases export
ISO
EXP
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; 4-fluoroamphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; 4-methylaminorex inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein; [SLC6A3 protein polymorphism affects the susceptibility to 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Bupropion] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Citalopram] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Cocaine] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate] which affects the uptake of Dopamine; [SNCA protein affects the localization of SLC6A3 protein] which affects the uptake of Dopamine; Amphetamine inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine]; Amphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Benztropine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; bisindolylmaleimide I inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Bupropion inhibits the reaction [SLC6A3 protein mutant form results in decreased import of Dopamine]; Bupropion inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Bupropion promotes the reaction [SLC6A3 protein results in increased import of Dopamine]; Butyrates inhibits the reaction [Cocaine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]]; Butyrates inhibits the reaction [Mazindol inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]]; Citalopram inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Cocaine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; decamethrin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Dextroamphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Fluoxetine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Ibogaine inhibits the reaction [SLC6A3 protein mutant form results in decreased import of Dopamine]; Ibogaine promotes the reaction [SLC6A3 protein results in increased import of Dopamine]; indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Ketamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; LRRK2 mutant form results in increased susceptibility to [Dopamine co-treated with SLC6A3 protein]; Mazindol inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Melitten inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Methylphenidate inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Nomifensine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; para-methyl-4-methylaminorex inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Permethrin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]; Sulpiride inhibits the reaction [Dopamine affects the localization of SLC6A3 protein]; Sulpiride inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; vanoxerine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Wortmannin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]
SLC6A3 protein polymorphism affects the uptake of Dopamine
SLC6A3 protein results in increased susceptibility to Dopamine
DAT protein results in increased uptake of Dopamine
SLC6A3 protein affects the export of Dopamine
[bisphenol A co-treated with Estradiol] inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; [Dichlorodiphenyl Dichloroethylene co-treated with Estradiol] promotes the reaction [SLC6A3 protein affects the export of Dopamine]; bisphenol A affects the reaction [SLC6A3 protein affects the export of Dopamine]; Cocaine promotes the reaction [SLC6A3 protein affects the uptake of Dopamine]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; Dieldrin inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; Diethylstilbestrol affects the reaction [SLC6A3 protein affects the export of Dopamine]; Endosulfan inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; Estradiol affects the reaction [SLC6A3 protein affects the export of Dopamine]; modafinil inhibits the reaction [SLC6A3 protein affects the uptake of Dopamine]; nonylphenol affects the reaction [SLC6A3 protein affects the export of Dopamine]
SLC6A3 protein affects the abundance of Dopamine
[Chlorodiphenyl (54% Chlorine) co-treated with aroclor 1260] inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; [decamethrin results in increased expression of SLC6A3 protein] which results in increased uptake of Dopamine; DDT inhibits the reaction [DAT protein results in increased uptake of Dopamine]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [DAT protein results in increased uptake of Dopamine]; Dichlorodiphenyldichloroethane inhibits the reaction [DAT protein results in increased uptake of Dopamine]; Heptachlor promotes the reaction [SLC6A3 protein results in increased uptake of Dopamine]; SLC6A3 mutant form affects the reaction [Cocaine affects the abundance of and affects the uptake of Dopamine]; SLC6A3 mutant form affects the reaction [Fluoxetine affects the abundance of Dopamine]; SLC6A3 mutant form promotes the reaction [Citalopram results in increased abundance of Dopamine]; SLC6A3 protein affects the reaction [[Cocaine co-treated with Alcohols] results in increased uptake of Dopamine]; SLC6A3 protein affects the reaction [Alcohols results in increased uptake of Dopamine]; SLC6A3 protein affects the reaction [Cocaine results in increased uptake of Dopamine]; SLC6A3 protein affects the reaction [Methamphetamine affects the abundance of Dopamine]; SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; vanoxerine inhibits the reaction [SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]
SLC6A3 protein results in increased transport of Dopamine
CTD PMID:9634552, PMID:11165777, PMID:11294980, PMID:11707631, PMID:12112414, PMID:14691264, PMID:16005927, PMID:16702228, PMID:17234900, PMID:17250655, PMID:18533268, PMID:18614672, PMID:18690110, PMID:19032594, PMID:19197004, PMID:19479021, PMID:20035724, PMID:20875051, PMID:20969853, PMID:22342763, PMID:23313730, PMID:23628791, PMID:25630971, PMID:27555326, PMID:29908239, PMID:30776375, PMID:31009648 NCBI chr 1:32,323,011...32,363,983
Ensembl chr 1:32,321,580...32,363,983
JBrowse link
G Slc6a4 solute carrier family 6 member 4 multiple interactions ISO Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein] CTD PMID:17234900 NCBI chr10:63,153,656...63,188,377
Ensembl chr10:63,153,651...63,176,463
JBrowse link
G Snca synuclein alpha increases response to substance
decreases abundance
affects uptake
multiple interactions
increases abundance
affects response to substance
affects abundance
ISO
EXP
SNCA gene mutant form results in increased susceptibility to Dopamine
SNCA protein results in decreased abundance of Dopamine
SNCA protein affects the uptake of Dopamine
[SNCA protein affects the localization of SLC6A3 protein] which affects the uptake of Dopamine; [SNCA protein co-treated with Dopamine] results in increased expression of HMOX1 protein; [SNCA protein co-treated with Paraquat co-treated with Dopamine] results in increased expression of HMOX1 protein; Dopamine inhibits the reaction [SNCA protein results in decreased abundance of Dopamine]; Dopamine inhibits the reaction [SNCA protein results in decreased abundance of Glutathione]; Dopamine inhibits the reaction [SNCA protein results in increased abundance of Thiobarbituric Acid Reactive Substances]; geraniol inhibits the reaction [SNCA protein results in decreased abundance of Dopamine]; TRAP1 protein inhibits the reaction [SNCA protein affects the abundance of Dopamine]
SNCA protein results in increased abundance of Dopamine
SNCA protein promotes the reaction [Rotenone results in decreased abundance of Dopamine]
SNCA protein mutant form results in decreased abundance of Dopamine
SNCA affects the susceptibility to Dopamine
CTD PMID:15234109, PMID:17131421, PMID:18622040, PMID:19032594, PMID:19409267, PMID:21735318, PMID:22319455, PMID:26075822, PMID:27026137 NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions
affects binding
decreases expression
EXP
ISO
[Copper Sulfate co-treated with Dopamine] results in decreased expression of SOD1 mRNA; [Dopamine co-treated with Dicumarol co-treated with Copper Sulfate] results in decreased expression of SOD1 mRNA
Dopamine binds to SOD1 protein mutant form
Dopamine results in decreased expression of SOD1 mRNA
CTD PMID:11299314, PMID:23612299 NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
JBrowse link
G Sod2 superoxide dismutase 2 increases expression
decreases expression
multiple interactions
EXP [Dopamine results in increased expression of HMOX1 mRNA] which results in increased expression of SOD2 mRNA; Dopamine results in increased expression of SOD2 mRNA
Dopamine results in decreased expression of SOD2 mRNA
[Dopamine co-treated with Dicumarol co-treated with Copper Sulfate] results in decreased expression of SOD2 mRNA
CTD PMID:10942521, PMID:11299314 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Ssbp1 single stranded DNA binding protein 1 increases expression ISO Dopamine results in increased expression of SSBP1 protein CTD PMID:24675778 NCBI chr 4:68,634,844...68,645,112
Ensembl chr 4:68,634,929...68,645,172
JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions
increases metabolic processing
ISO
EXP
Mefenamic Acid inhibits the reaction [SULT1A1 protein results in increased sulfation of Dopamine]
SULT1A1 protein results in increased metabolism of Dopamine
CTD PMID:10623578, PMID:11181495 NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
JBrowse link
G Syn1 synapsin I multiple interactions ISO SYN1 protein affects the reaction [Cocaine results in increased secretion of Dopamine] CTD PMID:16554471 NCBI chr  X:1,321,315...1,379,202
Ensembl chr  X:1,321,315...1,379,198
JBrowse link
G Syn2 synapsin II multiple interactions ISO SYN2 protein affects the reaction [Cocaine results in increased secretion of Dopamine] CTD PMID:16554471 NCBI chr 4:147,037,179...147,195,096
Ensembl chr 4:147,037,179...147,195,096
JBrowse link
G Syn3 synapsin III multiple interactions ISO SYN3 protein affects the reaction [Cocaine results in increased secretion of Dopamine] CTD PMID:16554471 NCBI chr 7:23,403,896...23,808,602
Ensembl chr 7:23,403,891...23,808,602
JBrowse link
G Taar1 trace-amine-associated receptor 1 multiple interactions ISO Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein] CTD PMID:17234900 NCBI chr 1:22,595,477...22,596,475
Ensembl chr 1:22,595,477...22,596,475
JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase multiple interactions EXP [Sulindac results in decreased activity of TDO2 protein] which results in decreased abundance of Dopamine; [Tolmetin results in decreased activity of TDO2 protein] which results in decreased abundance of Dopamine CTD PMID:16952380 NCBI chr 2:180,897,059...180,914,919
Ensembl chr 2:180,897,011...180,914,940
JBrowse link
G Tfam transcription factor A, mitochondrial decreases abundance ISO TFAM gene mutant form results in decreased abundance of Dopamine CTD PMID:28595911 NCBI chr20:18,594,057...18,606,106
Ensembl chr20:18,594,037...18,606,151
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression
multiple interactions
decreases expression
EXP Dopamine results in increased expression of TGFB1 mRNA
DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of TGFB1 protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of TGFB1 protein]
CTD PMID:16760913, PMID:25818600 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tgfb2 transforming growth factor, beta 2 increases expression EXP Dopamine results in increased expression of TGFB2 mRNA CTD PMID:16760913 NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
JBrowse link
G Th tyrosine hydroxylase increases chemical synthesis
affects abundance
decreases activity
multiple interactions
affects chemical synthesis
ISO
EXP
TH protein results in increased chemical synthesis of Dopamine
TH protein affects the abundance of Dopamine
TH affects the abundance of Dopamine
Dopamine results in decreased activity of TH protein
1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]; [1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog binds to and results in increased activity of HRH1 protein] promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]; [Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Dopamine; [Selenium deficiency results in increased activity of TH protein] which results in increased chemical synthesis of Dopamine; Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]; dicarbine inhibits the reaction [Dopamine results in decreased activity of TH protein]; Paraquat promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]; Spiperone inhibits the reaction [Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]]; Sulpiride inhibits the reaction [Dopamine results in decreased activity of TH protein]; Triprolidine inhibits the reaction [1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]]
TH protein affects the chemical synthesis of Dopamine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [[Clozapine results in increased activity of TH protein] which results in increased metabolism of Dopamine]; [Clozapine results in increased activity of TH protein] which results in increased metabolism of Dopamine; [TH protein affects the abundance of Dopamine] which affects the susceptibility to Methamphetamine; [TH protein affects the chemical synthesis of Dopamine] which affects the susceptibility to Methamphetamine
CTD PMID:2884129, PMID:8707341, PMID:9822156, PMID:10661506, PMID:10984662, PMID:11113527, PMID:16402076, PMID:16415089, PMID:19067675, PMID:19815691, PMID:20615977, PMID:20729865, PMID:24743698 NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
JBrowse link
G Thbs1 thrombospondin 1 increases expression EXP Dopamine results in increased expression of THBS1 mRNA CTD PMID:21983523 NCBI chr 3:109,862,120...109,873,466
Ensembl chr 3:109,862,117...109,873,466
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 increases expression EXP Dopamine results in increased expression of TIMP1 mRNA CTD PMID:21983523 NCBI chr  X:1,364,771...1,369,451
Ensembl chr  X:1,364,786...1,369,384
JBrowse link
G Tlr2 toll-like receptor 2 increases expression EXP Dopamine results in increased expression of TLR2 mRNA CTD PMID:21983523 NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
JBrowse link
G Tmem97 transmembrane protein 97 increases expression EXP Dopamine results in increased expression of TMEM97 mRNA CTD PMID:21983523 NCBI chr10:65,811,455...65,820,538
Ensembl chr10:65,811,456...65,820,538
JBrowse link
G Tnc tenascin C increases expression EXP Dopamine results in increased expression of TNC mRNA CTD PMID:21983523 NCBI chr 5:79,789,686...79,874,555
Ensembl chr 5:79,789,671...79,874,671
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
increases uptake
ISO
EXP
Dopamine promotes the reaction [TNF protein results in increased expression of F3 mRNA]; TNF protein inhibits the reaction [Methamphetamine results in decreased uptake of Dopamine]; TNF protein inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]
vanoxerine inhibits the reaction [Dopamine analog results in increased expression of TNF protein]
Dopamine results in increased expression of TNF protein
Bucladesine inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Colforsin inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; DRD2 mutant form inhibits the reaction [Dopamine results in increased expression of TNF protein]; eticlopride inhibits the reaction [Dopamine results in increased expression of TNF protein]; ICI 118551 inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Metoprolol inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Propranolol inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]
TNF protein results in increased uptake of Dopamine
CTD PMID:14999072, PMID:15081246, PMID:20118172, PMID:25818600, PMID:27026709 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfsf10 TNF superfamily member 10 decreases expression EXP Dopamine results in decreased expression of TNFSF10 mRNA CTD PMID:21983523 NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression
ISO [Dopamine results in increased expression of HIF1A protein] which results in increased expression of and results in increased phosphorylation of TP53 protein
[Dopamine results in increased expression of HIF1A protein] which results in increased expression of TP53 protein
CTD PMID:19410601 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Tpm4 tropomyosin 4 increases expression EXP Dopamine results in increased expression of TPM4 mRNA CTD PMID:21983523 NCBI chr16:19,385,810...19,399,851
Ensembl chr16:19,385,736...19,399,903
JBrowse link
G Trap1 TNF receptor-associated protein 1 multiple interactions ISO TRAP1 protein inhibits the reaction [SNCA protein affects the abundance of Dopamine] CTD PMID:22319455 NCBI chr10:11,724,032...11,757,682
Ensembl chr10:11,724,032...11,757,681
JBrowse link
G Tubb4b tubulin, beta 4B class IVb increases expression EXP Dopamine results in increased expression of TUBB4B mRNA CTD PMID:21983523 NCBI chr 3:2,441,585...2,444,369
Ensembl chr 3:2,441,733...2,444,281
JBrowse link
G Tubb5 tubulin, beta 5 class I increases expression
decreases expression
EXP
ISO
Dopamine results in increased expression of TUBB5 mRNA
Dopamine results in decreased expression of TUBB protein
CTD PMID:21983523, PMID:24675778 NCBI chr20:3,422,448...3,426,420
Ensembl chr20:3,422,461...3,426,371
JBrowse link
G Tubb6 tubulin, beta 6 class V increases expression EXP Dopamine results in increased expression of TUBB6 mRNA CTD PMID:21983523 NCBI chr18:63,130,542...63,140,181
Ensembl chr18:63,130,542...63,140,181
JBrowse link
G Tufm Tu translation elongation factor, mitochondrial increases expression ISO Dopamine results in increased expression of TUFM protein CTD PMID:24675778 NCBI chr 1:197,903,582...197,907,189
Ensembl chr 1:197,903,582...197,907,189
JBrowse link
G Ube2l3 ubiquitin-conjugating enzyme E2L 3 increases expression EXP Dopamine results in increased expression of UBE2L3 mRNA CTD PMID:21983523 NCBI chr11:88,047,186...88,088,477
Ensembl chr11:88,047,832...88,088,476
JBrowse link
G Vcan versican increases expression EXP Dopamine results in increased expression of VCAN mRNA CTD PMID:21983523 NCBI chr 2:18,490,102...18,587,340
Ensembl chr 2:18,490,102...18,565,842
JBrowse link
G Vdac1 voltage-dependent anion channel 1 increases expression ISO Dopamine results in increased expression of VDAC1 protein CTD PMID:24675778 NCBI chr10:37,724,915...37,752,827
Ensembl chr10:37,724,915...37,752,826
JBrowse link
G Vdac2 voltage-dependent anion channel 2 affects expression ISO Dopamine affects the expression of VDAC2 protein CTD PMID:24675778 NCBI chr15:2,634,622...2,648,548
Ensembl chr15:2,634,624...2,648,551
JBrowse link
G Vdr vitamin D receptor increases abundance ISO VDR protein results in increased abundance of Dopamine CTD PMID:27450565 NCBI chr 7:139,344,452...139,394,138
Ensembl chr 7:139,342,063...139,394,166
JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression
multiple interactions
EXP Dopamine results in decreased expression of VEGFA mRNA; Dopamine results in decreased expression of VEGFA protein
DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of VEGFA protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of VEGFA mRNA]; eticlopride inhibits the reaction [Dopamine results in decreased expression of VEGFA protein]
CTD PMID:25818600 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
N-acetyldopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mthfs methenyltetrahydrofolate synthetase affects binding ISO N-acetyldopamine binds to MTHFS protein CTD PMID:17055997 NCBI chr 8:96,564,877...96,614,386
Ensembl chr 8:96,564,877...96,614,348
JBrowse link
N-oleoyldopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cnr1 cannabinoid receptor 1 multiple interactions EXP N-oleoyldopamine binds to and results in increased activity of CNR1 protein CTD PMID:12569099 NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions
increases activity
ISO
EXP
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; iodoresiniferatoxin inhibits the reaction [[N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; iodoresiniferatoxin inhibits the reaction [N-oleoyldopamine results in increased activity of TRPV1 protein] CTD PMID:12569099, PMID:15615864 NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
JBrowse link
oxidopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc8 ATP binding cassette subfamily C member 8 increases expression EXP Oxidopamine results in increased expression of ABCC8 mRNA; Oxidopamine results in increased expression of ABCC8 protein CTD PMID:15857625 NCBI chr 1:102,110,708...102,191,287
Ensembl chr 1:102,110,708...102,191,287
JBrowse link
G Abcc9 ATP binding cassette subfamily C member 9 increases expression EXP Oxidopamine results in increased expression of ABCC9 mRNA; Oxidopamine results in increased expression of ABCC9 protein CTD PMID:15857625 NCBI chr 4:176,806,098...176,928,540
Ensembl chr 4:176,805,431...176,922,424
JBrowse link
G Aco1 aconitase 1 increases expression
multiple interactions
affects response to substance
ISO Oxidopamine results in increased expression of ACO1 mRNA
[ACO1 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA; Oxidopamine promotes the reaction [ACO1 protein results in decreased expression of SLC40A1 mRNA]
CTD PMID:19913091 NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
JBrowse link
G Adora2a adenosine A2a receptor multiple interactions EXP 8-(3-chlorostyryl)caffeine inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of ADORA2A protein]; [Oxidopamine co-treated with Levodopa] results in increased expression of ADORA2A mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of ADORA2A protein CTD PMID:15065221, PMID:21195062 NCBI chr20:14,265,251...14,282,873
Ensembl chr20:14,265,252...14,282,873
JBrowse link
G Ager advanced glycosylation end product-specific receptor affects expression
affects binding
EXP Oxidopamine affects the expression of AGER protein
Oxidopamine binds to AGER protein
CTD PMID:26902637 NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions
affects localization
ISO alpha-iso-cubebenol inhibits the reaction [Oxidopamine affects the localization of AIFM1 protein]; Selegiline inhibits the reaction [Oxidopamine affects the localization of AIFM1 protein] CTD PMID:12880480, PMID:24997245 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation
EXP Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]; Oxidopamine results in increased phosphorylation of and results in increased activity of AKT1 protein CTD PMID:16339297, PMID:21397656 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Akt2 AKT serine/threonine kinase 2 multiple interactions
decreases phosphorylation
EXP Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein] CTD PMID:16339297 NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
JBrowse link
G Akt3 AKT serine/threonine kinase 3 multiple interactions
decreases phosphorylation
EXP Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein] CTD PMID:16339297 NCBI chr13:95,076,308...95,348,913
Ensembl chr13:95,081,390...95,348,913
JBrowse link
G Atf4 activating transcription factor 4 increases expression EXP Oxidopamine results in increased expression of ATF4 mRNA; Oxidopamine results in increased expression of ATF4 protein CTD PMID:12486162 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atxn2 ataxin 2 multiple interactions
increases expression
EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA] CTD PMID:25129099 NCBI chr12:40,264,601...40,335,637
Ensembl chr12:40,266,662...40,332,612
JBrowse link
G Atxn3 ataxin 3 multiple interactions
increases expression
EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA] CTD PMID:25129099 NCBI chr 6:125,817,420...125,853,461
Ensembl chr 6:125,819,640...125,853,461
JBrowse link
G Avpr2 arginine vasopressin receptor 2 increases expression EXP Oxidopamine results in increased expression of AVPR2 mRNA CTD PMID:15303306 NCBI chr  X:156,889,006...156,892,707
Ensembl chr  X:156,889,410...156,891,213
JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects localization
increases expression
multiple interactions
ISO
EXP
Oxidopamine affects the localization of BAX protein
Oxidopamine results in increased expression of BAX mRNA; Oxidopamine results in increased expression of BAX protein
tricetin inhibits the reaction [Oxidopamine results in increased expression of BAX mRNA]; tricetin inhibits the reaction [Oxidopamine results in increased expression of BAX protein]
5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in increased expression of BAX protein]; Tea inhibits the reaction [Oxidopamine results in increased expression of BAX protein]
CTD PMID:16480889, PMID:21397656, PMID:22821850, PMID:28802652, PMID:31176653 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression
ISO
EXP
PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]]; pyrazolanthrone inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; tricetin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 mRNA]; tricetin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]
5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; Tea inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]
Oxidopamine results in decreased expression of BCL2 mRNA; Oxidopamine results in decreased expression of BCL2 protein
CTD PMID:16480889, PMID:21397656, PMID:25446857, PMID:28802652, PMID:30707903, PMID:31176653 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bdnf brain-derived neurotrophic factor decreases expression
multiple interactions
ISO Oxidopamine results in decreased expression of BDNF protein
chrysin inhibits the reaction [Oxidopamine results in decreased expression of BDNF protein]
CTD PMID:29054324 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Calr calreticulin increases expression EXP Oxidopamine results in increased expression of CALR mRNA CTD PMID:12486162 NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
JBrowse link
G Casp1 caspase 1 increases expression
multiple interactions
EXP Oxidopamine results in increased expression of CASP1 mRNA
Levodopa inhibits the reaction [Oxidopamine results in increased expression of CASP1 mRNA]
CTD PMID:25129099 NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
JBrowse link
G Casp3 caspase 3 increases activity
affects activity
increases expression
increases cleavage
multiple interactions
ISO
EXP
Oxidopamine results in increased activity of CASP3 protein
Oxidopamine affects the activity of CASP3 protein
Oxidopamine results in increased expression of CASP3 mRNA; Oxidopamine results in increased expression of CASP3 protein modified form
Oxidopamine results in increased cleavage of CASP3 protein
3-methyladenine inhibits the reaction [Oxidopamine results in increased expression of CASP3 protein modified form]; 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of CASP3 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; MDL 201053 inhibits the reaction [Oxidopamine results in increased expression of CASP3 protein modified form]; MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; Rutin inhibits the reaction [Oxidopamine results in increased expression of CASP3 mRNA]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]
sulforafan inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]
Caffeine inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; ginsenoside Rb1 inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; Oxidopamine results in increased expression of and results in increased activity of CASP3 protein; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; pinostilbene inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; Plant Extracts inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; puag-haad inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; Resveratrol inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; sulforafan inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; tricetin inhibits the reaction [Oxidopamine results in increased expression of and results in increased activity of CASP3 protein]
CTD PMID:18201823, PMID:18675900, PMID:19443200, PMID:19780897, PMID:19781563, PMID:20040370, PMID:21397656, PMID:21846476, PMID:23518299, PMID:25129099, PMID:25271104, PMID:25446857, PMID:28802652, PMID:30707903, PMID:31176653, PMID:31705926, PMID:31778666 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 multiple interactions
increases expression
EXP Levodopa inhibits the reaction [Oxidopamine results in increased expression of CASP7 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of CASP7 mRNA] CTD PMID:25129099 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp9 caspase 9 increases activity
multiple interactions
ISO
EXP
Oxidopamine results in increased activity of CASP9 protein
sulforafan inhibits the reaction [Oxidopamine results in increased activity of CASP9 protein]
CTD PMID:19780897, PMID:19781563, PMID:21846476 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase decreases activity
multiple interactions
EXP Oxidopamine results in decreased activity of CAT protein
Tea inhibits the reaction [Oxidopamine results in decreased activity of CAT protein]
CTD PMID:16480889 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cd2ap CD2-associated protein increases expression ISO Oxidopamine results in increased expression of CD2AP mRNA CTD PMID:18535749 NCBI chr 9:20,794,680...20,858,438
Ensembl chr 9:20,765,296...20,858,504
JBrowse link
G Cdk5 cyclin-dependent kinase 5 multiple interactions EXP [Oxidopamine co-treated with Levodopa] results in increased expression of CDK5 protein CTD PMID:17188499 NCBI chr 4:7,282,945...7,287,427
Ensembl chr 4:7,282,948...7,288,383
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression EXP Oxidopamine results in increased expression of CEBPB mRNA CTD PMID:12486162 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
JBrowse link
G Cnr1 cannabinoid receptor 1 affects response to substance ISO CNR1 affects the susceptibility to Oxidopamine CTD PMID:19419794 NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
JBrowse link
G Comt catechol-O-methyltransferase increases methylation ISO COMT protein results in increased methylation of Oxidopamine CTD PMID:11160877 NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions
increases expression
ISO N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in increased expression of CYBB protein] CTD PMID:17855475 NCBI chr  X:14,578,330...14,610,049
Ensembl chr  X:14,578,264...14,612,547
JBrowse link
G Ddc dopa decarboxylase decreases expression
multiple interactions
EXP Oxidopamine results in decreased expression of DDC protein
Levodopa inhibits the reaction [Oxidopamine results in decreased expression of DDC protein]
CTD PMID:20232137 NCBI chr14:91,905,919...91,996,816
Ensembl chr14:91,905,919...91,996,774
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression EXP Oxidopamine results in increased expression of DDIT3 mRNA; Oxidopamine results in increased expression of DDIT3 protein CTD PMID:12486162 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 affects localization
decreases expression
multiple interactions
EXP Oxidopamine affects the localization of DLG1 protein
Oxidopamine results in decreased expression of DLG1 protein
[Oxidopamine co-treated with Levodopa] results in increased expression of DLG1 mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of DLG1 protein
CTD PMID:15703272 NCBI chr11:72,164,566...72,378,895
Ensembl chr11:72,163,749...72,378,895
JBrowse link
G Dlg4 discs large MAGUK scaffold protein 4 multiple interactions
decreases expression
affects localization
EXP [Oxidopamine co-treated with Levodopa] results in increased expression of DLG4 mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of DLG4 protein
Oxidopamine results in decreased expression of DLG4 mRNA; Oxidopamine results in decreased expression of DLG4 protein
Oxidopamine affects the localization of DLG4 protein
CTD PMID:15703272 NCBI chr10:56,625,845...56,655,543
Ensembl chr10:56,627,411...56,653,599
JBrowse link
G Dnaja2 DnaJ heat shock protein family (Hsp40) member A2 increases expression EXP Oxidopamine results in increased expression of DNAJA2 mRNA CTD PMID:12486162 NCBI chr19:22,569,999...22,588,143
Ensembl chr19:22,569,999...22,588,137
JBrowse link
G Dnaja3 DnaJ heat shock protein family (Hsp40) member A3 increases degradation
decreases expression
EXP
ISO
Oxidopamine results in increased degradation of DNAJA3 protein
Oxidopamine results in decreased expression of DNAJA3 protein
CTD PMID:22016808 NCBI chr10:11,059,701...11,085,186
Ensembl chr10:11,060,313...11,085,210
JBrowse link
G Dnm1l dynamin 1-like affects localization
increases expression
multiple interactions
ISO Oxidopamine affects the localization of DNM1L protein
Oxidopamine results in increased expression of DNM1L protein
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [Oxidopamine affects the localization of DNM1L protein]
CTD PMID:22821850, PMID:31705926 NCBI chr11:88,830,968...88,882,271
Ensembl chr11:88,830,957...88,880,198
JBrowse link
G Drd1 dopamine receptor D1 multiple interactions
increases expression
decreases expression
EXP [Levodopa co-treated with Oxidopamine] results in increased expression of DRD1 mRNA; [Oxidopamine co-treated with levodopa methyl ester] promotes the reaction [Benserazide results in increased expression of DRD1 protein]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of DRD1 protein]
Oxidopamine results in increased expression of DRD1 protein
Oxidopamine results in decreased expression of DRD1 mRNA; Oxidopamine results in decreased expression of DRD1 protein
CTD PMID:16365282, PMID:18707801, PMID:19118628, PMID:19399396 NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
JBrowse link
G Drd2 dopamine receptor D2 multiple interactions
increases expression
EXP [Oxidopamine co-treated with levodopa methyl ester] inhibits the reaction [Benserazide results in increased expression of DRD2 protein]; Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]; Tea inhibits the reaction [Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]]
Oxidopamine results in increased expression of DRD2 mRNA; Oxidopamine results in increased expression of DRD2 protein
CTD PMID:16480889, PMID:19118628, PMID:19399396 NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
JBrowse link
G Drd3 dopamine receptor D3 multiple interactions
decreases expression
EXP [Levodopa co-treated with Oxidopamine] results in increased expression of DRD3 mRNA; [Levodopa co-treated with Oxidopamine] results in increased expression of DRD3 protein; Oxidopamine inhibits the reaction [7-hydroxy-2-N,N-dipropylaminotetralin binds to DRD3 protein]
Oxidopamine results in decreased expression of DRD3 mRNA
CTD PMID:7878047, PMID:17241287, PMID:19118628 NCBI chr11:61,819,102...61,883,223
Ensembl chr11:61,822,077...61,874,327
JBrowse link
G Drd4 dopamine receptor D4 increases expression EXP Oxidopamine results in increased expression of DRD4 mRNA CTD PMID:15303306 NCBI chr 1:214,278,296...214,282,818
Ensembl chr 1:214,278,296...214,281,483
JBrowse link
G Egf epidermal growth factor decreases activity EXP Oxidopamine results in decreased activity of EGF protein CTD PMID:9324159 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egln1 egl-9 family hypoxia-inducible factor 1 multiple interactions
increases expression
EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA] CTD PMID:25129099 NCBI chr19:57,660,194...57,701,158
Ensembl chr19:57,662,278...57,699,113
JBrowse link
G Egr1 early growth response 1 multiple interactions EXP [Oxidopamine co-treated with Levodopa] results in increased expression of EGR1 mRNA CTD PMID:9890435 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A multiple interactions EXP Oxidopamine results in increased phosphorylation of and results in increased activity of EIF2A protein CTD PMID:12486162 NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 affects response to substance
multiple interactions
ISO
EXP
EIF2AK3 protein affects the susceptibility to Oxidopamine
Oxidopamine results in increased phosphorylation of and results in increased activity of EIF2AK3 protein
CTD PMID:12486162 NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
JBrowse link
G En1 engrailed homeobox 1 multiple interactions ISO [EN1 protein co-treated with EN2 protein] results in decreased susceptibility to Oxidopamine CTD PMID:21892157 NCBI chr13:36,532,758...36,537,888
Ensembl chr13:36,532,758...36,537,093
JBrowse link
G En2 engrailed homeobox 2 multiple interactions ISO [EN1 protein co-treated with EN2 protein] results in decreased susceptibility to Oxidopamine CTD PMID:21892157 NCBI chr 4:438,668...444,508
Ensembl chr 4:438,668...444,501
JBrowse link
G Ephb1 Eph receptor B1 decreases expression ISO Oxidopamine results in decreased expression of EPHB1 protein CTD PMID:11146119 NCBI chr 8:110,376,954...110,813,193
Ensembl chr 8:110,376,954...110,813,000
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions EXP Oxidopamine results in increased phosphorylation of and results in increased activity of ERN1 protein CTD PMID:12486162 NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
JBrowse link
G Esr1 estrogen receptor 1 increases expression EXP Oxidopamine results in increased expression of ESR1 mRNA CTD PMID:12486162 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Fgf10 fibroblast growth factor 10 increases expression EXP Oxidopamine results in increased expression of FGF10 mRNA CTD PMID:15303306 NCBI chr 2:51,673,480...51,747,533
Ensembl chr 2:51,672,722...51,750,369
JBrowse link
G Fis1 fission, mitochondrial 1 increases expression
multiple interactions
ISO Oxidopamine results in increased expression of FIS1 protein
salvin inhibits the reaction [Oxidopamine results in increased expression of FIS1 protein]
CTD PMID:31705926 NCBI chr12:22,750,485...22,765,324
Ensembl chr12:22,750,485...22,765,308
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
decreases expression
EXP [Levodopa co-treated with Oxidopamine] results in increased expression of FOS protein; [Oxidopamine co-treated with Levodopa] results in increased expression of FOS mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of FOS protein; GDNF protein inhibits the reaction [Oxidopamine inhibits the reaction [Amphetamine results in increased expression of FOS protein]]; Oxidopamine inhibits the reaction [Amphetamine results in increased expression of FOS protein]
Oxidopamine results in decreased expression of FOS protein
CTD PMID:11031079, PMID:14526427, PMID:16325000, PMID:16706847, PMID:17329435 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Fosb FosB proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
ISO
EXP
[Levodopa co-treated with Oxidopamine] results in increased expression of FOSB protein; [Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein
Oxidopamine results in increased expression of FOSB protein
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Levodopa co-treated with Oxidopamine] results in increased expression of FOSB protein]; [Levodopa co-treated with Oxidopamine] results in increased expression of FOSB protein; [Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein]; Levodopa promotes the reaction [Oxidopamine results in increased expression of FOSB protein]
CTD PMID:12127155, PMID:15207268, PMID:15659429, PMID:16095907, PMID:16139809, PMID:17933546, PMID:19520364 NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
JBrowse link
G Gad1 glutamate decarboxylase 1 multiple interactions
increases expression
EXP 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of GAD1 mRNA]]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of GAD1 mRNA]; Levodopa promotes the reaction [Oxidopamine results in increased expression of GAD1 mRNA] CTD PMID:12077209, PMID:15044549, PMID:15610165, PMID:17241287, PMID:19660528 NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157
JBrowse link
G Gad2 glutamate decarboxylase 2 multiple interactions
increases expression
EXP Levodopa promotes the reaction [Oxidopamine results in increased expression of GAD2 mRNA] CTD PMID:19660528 NCBI chr17:89,171,576...89,234,770
Ensembl chr17:89,171,250...89,238,040
JBrowse link
G Galr2 galanin receptor 2 decreases expression
increases expression
EXP Oxidopamine results in decreased expression of GALR2 mRNA
Oxidopamine results in increased expression of GALR2 mRNA
CTD PMID:15303306, PMID:15518916 NCBI chr10:105,156,793...105,159,221
Ensembl chr10:105,156,632...105,237,611
JBrowse link
G Gch1 GTP cyclohydrolase 1 multiple interactions EXP [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein]; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; [TH co-treated with GCH1] inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]] CTD PMID:15659429 NCBI chr15:23,935,011...23,968,971
Ensembl chr15:23,934,585...23,969,011
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit decreases expression
multiple interactions
increases expression
ISO
EXP
Oxidopamine results in decreased expression of GCLC protein
salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLC protein]
Oxidopamine results in increased expression of GCLC mRNA; Oxidopamine results in increased expression of GCLC protein
CTD PMID:21397656, PMID:25446857 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit decreases expression
multiple interactions
ISO
EXP
Oxidopamine results in decreased expression of GCLM protein
salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLM protein]
CTD PMID:25446857 NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
JBrowse link
G Gdnf glial cell derived neurotrophic factor affects response to substance
decreases expression
multiple interactions
ISO
EXP
GDNF protein affects the susceptibility to Oxidopamine
Oxidopamine results in decreased expression of GDNF protein
chrysin inhibits the reaction [Oxidopamine results in decreased expression of GDNF protein]
GDNF protein affects the susceptibility to [Apomorphine co-treated with Oxidopamine]; GDNF protein affects the susceptibility to [Dextroamphetamine co-treated with Oxidopamine]; GDNF protein affects the susceptibility to [Oxidopamine co-treated with Amphetamine]; GDNF protein affects the susceptibility to [Oxidopamine co-treated with Dextroamphetamine]; GDNF protein inhibits the reaction [Oxidopamine inhibits the reaction [Amphetamine results in increased expression of FOS protein]]
GDNF protein inhibits the reaction [Oxidopamine results in decreased secretion of Dopamine]
CTD PMID:11031079, PMID:11312561, PMID:11771942, PMID:12213621, PMID:12429192, PMID:29054324 NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
JBrowse link
G Gfap glial fibrillary acidic protein decreases expression
increases expression
multiple interactions
EXP Oxidopamine results in decreased expression of GFAP protein
Oxidopamine results in increased expression of GFAP protein
rosiglitazone promotes the reaction [Oxidopamine results in increased expression of GFAP protein]
CTD PMID:22842585, PMID:24486959 NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 decreases expression EXP Oxidopamine results in decreased expression of GRIA2 mRNA CTD PMID:11290405 NCBI chr 2:179,584,302...179,704,629
Ensembl chr 2:179,584,308...179,704,629
JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 decreases expression
multiple interactions
EXP Oxidopamine results in decreased expression of GRIN1 mRNA; Oxidopamine results in decreased expression of GRIN1 protein alternative form
Levodopa inhibits the reaction [Oxidopamine results in decreased expression of GRIN1 protein alternative form]
CTD PMID:15518916, PMID:16365282 NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
JBrowse link
G Grin2b glutamate ionotropic receptor NMDA type subunit 2B multiple interactions
decreases expression
EXP Levodopa inhibits the reaction [Oxidopamine results in decreased expression of GRIN2B protein] CTD PMID:16365282 NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
JBrowse link
G Grm1 glutamate metabotropic receptor 1 multiple interactions ISO [benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of GRM1 protein CTD PMID:17596448 NCBI chr 1:4,753,141...5,165,859
Ensembl chr 1:4,753,144...5,165,859
JBrowse link
G Gsr glutathione-disulfide reductase decreases expression
multiple interactions
decreases activity
ISO
EXP
Oxidopamine results in decreased expression of GSR protein
salvin inhibits the reaction [Oxidopamine results in decreased expression of GSR protein]
sulforafan inhibits the reaction [Oxidopamine results in decreased activity of GSR protein]
CTD PMID:23518299, PMID:25446857 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions
decreases expression
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein] CTD PMID:25271104 NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
JBrowse link
G Hax1 HCLS1 associated protein X-1 increases expression ISO Oxidopamine results in increased expression of HAX1 protein CTD PMID:19763263 NCBI chr 2:189,330,900...189,333,305
Ensembl chr 2:189,330,902...189,333,322
JBrowse link
G Heph hephaestin decreases expression
multiple interactions
ISO Oxidopamine results in decreased expression of HEPH mRNA; Oxidopamine results in decreased expression of HEPH protein
[ACO1 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA; [IREB2 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA
CTD PMID:19913091 NCBI chr  X:65,377,313...65,658,479
Ensembl chr  X:65,563,122...65,658,516
JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 increases expression EXP Oxidopamine results in increased expression of HERPUD1 mRNA CTD PMID:12486162 NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254
JBrowse link
G Hes1 hes family bHLH transcription factor 1 affects expression
multiple interactions
EXP
ISO
Oxidopamine affects the expression of HES1 protein
MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]
CTD PMID:31778666 NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
decreases expression
ISO
EXP
N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in decreased expression of HMOX1 protein]
Oxidopamine results in increased expression of HMOX1 mRNA; Oxidopamine results in increased expression of HMOX1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; [5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride results in decreased abundance of Peroxynitrous Acid] inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; Acetylcysteine inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; U 0126 inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]
CTD PMID:17676812, PMID:17855475, PMID:21397656 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases expression ISO Oxidopamine results in increased expression of HPGD mRNA CTD PMID:31247335 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 increases expression EXP Oxidopamine results in increased expression of HSP90AB1 mRNA CTD PMID:12486162 NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
JBrowse link
G Hsp90b1 heat shock protein 90 beta family member 1 increases expression EXP Oxidopamine results in increased expression of HSP90B1 mRNA CTD PMID:12486162 NCBI chr 7:27,226,570...27,240,533
Ensembl chr 7:27,226,569...27,240,533
JBrowse link
G Hspa1l heat shock protein family A (Hsp70) member 1 like increases expression EXP Oxidopamine results in increased expression of HSPA1L mRNA CTD PMID:12486162 NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
JBrowse link
G Hspa4 heat shock protein family A (Hsp70) member 4 increases expression EXP Oxidopamine results in increased expression of HSPA4 mRNA CTD PMID:12486162 NCBI chr10:38,601,624...38,642,397
Ensembl chr10:38,601,624...38,642,397
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression EXP Oxidopamine results in increased expression of HSPA5 mRNA; Oxidopamine results in increased expression of HSPA5 protein CTD PMID:12486162 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Hspa8 heat shock protein family A (Hsp70) member 8 increases expression ISO
EXP
Oxidopamine results in increased expression of HSPA8 mRNA CTD PMID:12486162, PMID:19763263 NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
JBrowse link
G Hspb1 heat shock protein family B (small) member 1 increases expression EXP Oxidopamine results in increased expression of HSPB1 mRNA CTD PMID:12486162 NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
JBrowse link
G Hspe1 heat shock protein family E (Hsp10) member 1 increases expression EXP Oxidopamine results in increased expression of HSPE1 mRNA CTD PMID:12486162 NCBI chr 9:61,691,246...61,724,948
Ensembl chr 9:61,692,154...61,694,599
JBrowse link
G Htr1a 5-hydroxytryptamine receptor 1A decreases expression
multiple interactions
EXP Oxidopamine results in decreased expression of HTR1A mRNA
stepholidine inhibits the reaction [Oxidopamine results in decreased expression of HTR1A mRNA]
CTD PMID:18707801 NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
JBrowse link
G Htra2 HtrA serine peptidase 2 increases expression ISO Oxidopamine results in increased expression of HTRA2 mRNA; Oxidopamine results in increased expression of HTRA2 protein CTD PMID:19763263 NCBI chr 4:113,883,671...113,886,833
Ensembl chr 4:113,883,670...113,886,994
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions EXP Oxidopamine inhibits the reaction [Freund's Adjuvant results in increased expression of ICAM1] CTD PMID:20600813 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha decreases expression ISO Oxidopamine results in decreased expression of IDH3A mRNA CTD PMID:19763263 NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908
JBrowse link
G Ifng interferon gamma increases expression
multiple interactions
ISO Oxidopamine results in increased expression of IFNG protein
chrysin inhibits the reaction [Oxidopamine results in increased expression of IFNG protein]
CTD PMID:29054324 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression
ISO chrysin inhibits the reaction [Oxidopamine results in decreased expression of IL10 protein] CTD PMID:29054324 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
ISO chrysin inhibits the reaction [Oxidopamine results in increased expression of IL1B protein] CTD PMID:29054324 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il2 interleukin 2 increases expression ISO Oxidopamine results in increased expression of IL2 protein CTD PMID:29054324 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il6 interleukin 6 increases expression
multiple interactions
ISO Oxidopamine results in increased expression of IL6 protein
chrysin inhibits the reaction [Oxidopamine results in increased expression of IL6 protein]
CTD PMID:29054324 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Ireb2 iron responsive element binding protein 2 increases expression
multiple interactions
ISO Oxidopamine results in increased expression of IREB2 mRNA
[IREB2 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA; Oxidopamine promotes the reaction [IREB2 protein results in decreased expression of SLC40A1 mRNA]
CTD PMID:19913091 NCBI chr 8:59,450,974...59,503,634
Ensembl chr 8:59,420,123...59,501,118
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases phosphorylation
ISO Apomorphine inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein]; pinostilbene inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein]; puag-haad inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein]
Acetylcysteine inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]
CTD PMID:10397638, PMID:14599342, PMID:18675900, PMID:19443200 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Oxidopamine co-treated with Levodopa] results in increased expression of JUNB mRNA; Dizocilpine Maleate inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of JUNB mRNA]; eticlopride affects the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of JUNB mRNA]; Oxidopamine results in increased localization of and results in increased activity of JUNB protein CTD PMID:9890435, PMID:17368433 NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
JBrowse link
G Kcnj11 potassium inwardly-rectifying channel, subfamily J, member 11 increases expression EXP Oxidopamine results in increased expression of KCNJ11 mRNA; Oxidopamine results in increased expression of KCNJ11 protein CTD PMID:15857625 NCBI chr 1:102,103,093...102,107,134
Ensembl chr 1:102,103,094...102,106,127
JBrowse link
G Kcnj8 potassium inwardly-rectifying channel, subfamily J, member 8 increases expression EXP Oxidopamine results in increased expression of KCNJ8 mRNA; Oxidopamine results in increased expression of KCNJ8 protein CTD PMID:15857625 NCBI chr 4:176,783,287...176,789,143
Ensembl chr 4:176,782,498...176,789,304
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects response to substance ISO KEAP1 mRNA affects the susceptibility to Oxidopamine CTD PMID:16092930 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Lonp1 lon peptidase 1, mitochondrial increases expression EXP Oxidopamine results in increased expression of LONP1 mRNA CTD PMID:12486162 NCBI chr 9:10,428,853...10,441,180
Ensembl chr 9:10,428,853...10,441,177
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression EXP Oxidopamine results in increased expression of MAP1LC3B protein modified form CTD PMID:28802652 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions
ISO
EXP
Oxidopamine results in increased phosphorylation of MAPK1 protein
Oxidopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein
[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein; [Levodopa co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein; [Oxidopamine co-treated with Levodopa] results in increased expression of MAPK1 protein; [Oxidopamine co-treated with Levodopa] results in increased phosphorylation of MAPK1 protein; SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of MAPK1 protein]; SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein]; sulforafan inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]
alpha-iso-cubebenol inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]
CTD PMID:16139809, PMID:17596448, PMID:19187092, PMID:19520364, PMID:21397656, PMID:22016808, PMID:23518299, PMID:24997245, PMID:31176653 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO
EXP
alpha-iso-cubebenol inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein]
Oxidopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein
[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK3 protein; [Levodopa co-treated with Oxidopamine] results in increased phosphorylation of MAPK3 protein; [Oxidopamine co-treated with Levodopa] results in increased expression of MAPK3 protein; [Oxidopamine co-treated with Levodopa] results in increased phosphorylation of MAPK3 protein; SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of MAPK3 protein]; SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK3 protein]; sulforafan inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein]
CTD PMID:16139809, PMID:17596448, PMID:19187092, PMID:19520364, PMID:21397656, PMID:22016808, PMID:23518299, PMID:24997245, PMID:31176653 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions
ISO
EXP
Oxidopamine results in increased phosphorylation of MAPK8 protein
salvin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]
puag-haad inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; tricetin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]
Acetylcysteine inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]
CTD PMID:10397638, PMID:18675900, PMID:25446857, PMID:31176653 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 increases phosphorylation
multiple interactions
ISO
EXP
Oxidopamine results in increased phosphorylation of MAPK9 protein
salvin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK9 protein]
puag-haad inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK9 protein]
CTD PMID:18675900, PMID:25446857 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mapt microtubule-associated protein tau multiple interactions EXP Oxidopamine results in increased cleavage of and results in decreased phosphorylation of MAPT protein CTD PMID:12686375 NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
JBrowse link
G Mfn2 mitofusin 2 multiple interactions
decreases expression
ISO salvin inhibits the reaction [Oxidopamine results in decreased expression of MFN2 protein] CTD PMID:31705926 NCBI chr 5:164,684,244...164,715,414
Ensembl chr 5:164,684,509...164,714,145
JBrowse link
G Mir107 microRNA 107 decreases expression
multiple interactions
ISO
EXP
Oxidopamine results in decreased expression of MIR107 mRNA
MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]]
[Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 mRNA; [Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 protein; MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]; Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]]
CTD PMID:31778666 NCBI chr 1:253,128,250...253,128,336
Ensembl chr 1:253,128,250...253,128,336
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
increases expression
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased expression of MMP9 mRNA]; Acetylcysteine inhibits the reaction [Oxidopamine results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [Oxidopamine results in increased expression of MMP9 mRNA] CTD PMID:19962414 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mt2A metallothionein 2A decreases response to substance EXP MT2A protein results in decreased susceptibility to Oxidopamine CTD PMID:14604781 NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression EXP Oxidopamine results in increased expression of MYC protein CTD PMID:17368433 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Naip6 NLR family, apoptosis inhibitory protein 6 decreases response to substance EXP NAIP protein results in decreased susceptibility to Oxidopamine CTD PMID:11553289 NCBI chr 2:30,377,505...30,418,578 JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions
decreases expression
increases localization
increases expression
increases activity
decreases response to substance
ISO
EXP
[2-tert-butylhydroquinone results in increased expression of NFE2L2 protein] which results in decreased susceptibility to Oxidopamine; [linsidomine results in increased expression of NFE2L2 protein] which results in decreased susceptibility to Oxidopamine
Oxidopamine results in decreased expression of NFE2L2 protein
Oxidopamine results in increased localization of NFE2L2 protein
Oxidopamine results in increased expression of NFE2L2 mRNA; Oxidopamine results in increased expression of NFE2L2 protein
Oxidopamine results in increased activity of NFE2L2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased expression of NFE2L2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased localization of NFE2L2 protein]
NFE2L2 protein results in decreased susceptibility to Oxidopamine
CTD PMID:16092930, PMID:17676812, PMID:21397656, PMID:29057453 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkbia NFKB inhibitor alpha decreases expression
increases phosphorylation
ISO Oxidopamine results in decreased expression of NFKBIA protein
Oxidopamine results in increased phosphorylation of NFKBIA protein
CTD PMID:20851755, PMID:31247335 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Ngf nerve growth factor multiple interactions
decreases expression
ISO chrysin inhibits the reaction [Oxidopamine results in decreased expression of NGF protein] CTD PMID:29054324 NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
JBrowse link
G Nos1 nitric oxide synthase 1 multiple interactions
increases expression
ISO N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in increased expression of NOS1 protein] CTD PMID:17855475 NCBI chr12:44,214,949...44,405,530
Ensembl chr12:44,213,943...44,520,341
JBrowse link
G Nos2 nitric oxide synthase 2 increases expression
multiple interactions
ISO
EXP
Oxidopamine results in increased expression of NOS2 protein
[Oxidopamine results in increased expression of NOS2 protein] which results in increased secretion of Nitrites
N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in increased expression of NOS2 protein]
CTD PMID:17855475, PMID:21397656 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Notch1 notch receptor 1 multiple interactions
affects expression
ISO
EXP
MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]] CTD PMID:31778666 NCBI chr 3:3,905,562...3,951,015
Ensembl chr 3:3,905,453...3,951,025
JBrowse link
G Npy neuropeptide Y decreases expression
increases expression
EXP Oxidopamine results in decreased expression of NPY protein
Oxidopamine results in increased expression of NPY mRNA
CTD PMID:3805164, PMID:9460767, PMID:15303306 NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression EXP Oxidopamine results in increased expression of NQO1 mRNA; Oxidopamine results in increased expression of NQO1 protein CTD PMID:21397656 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nsf N-ethylmaleimide sensitive factor, vesicle fusing ATPase decreases expression
multiple interactions
EXP Oxidopamine results in decreased expression of NSF mRNA
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA]
CTD PMID:25129099 NCBI chr10:91,879,608...91,986,242
Ensembl chr10:91,878,633...92,008,082
JBrowse link
G Nsg1 neuronal vesicle trafficking associated 1 decreases expression
multiple interactions
EXP Oxidopamine results in decreased expression of NSG1 mRNA
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSG1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of NSG1 mRNA]
CTD PMID:25129099 NCBI chr14:77,380,264...77,402,007
Ensembl chr14:77,380,262...77,401,996
JBrowse link
G Opa1 OPA1, mitochondrial dynamin like GTPase multiple interactions
decreases expression
EXP
ISO
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA]
Oxidopamine results in decreased expression of OPA1 protein
OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 protein]
CTD PMID:25129099, PMID:31705926 NCBI chr11:74,717,600...74,793,902
Ensembl chr11:74,720,254...74,793,803
JBrowse link
G Oprl1 opioid related nociceptin receptor 1 decreases expression EXP Oxidopamine results in decreased expression of OPRL1 mRNA CTD PMID:19162046 NCBI chr 3:177,223,779...177,231,663
Ensembl chr 3:177,225,737...177,231,663
JBrowse link
G P4hb prolyl 4-hydroxylase subunit beta increases expression EXP Oxidopamine results in increased expression of P4HB mRNA CTD PMID:12486162 NCBI chr10:109,736,459...109,748,070
Ensembl chr10:109,736,458...109,747,987
JBrowse link
G Park7 Parkinsonism associated deglycase multiple interactions
increases expression
decreases response to substance
affects localization
ISO
EXP
Oxidopamine promotes the reaction [Quinones binds to PARK7 protein]
Oxidopamine results in increased expression of PARK7 mRNA
[4-phenylbutyric acid results in increased expression of PARK7 protein] which results in decreased susceptibility to Oxidopamine; isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA]
PARK7 protein results in decreased susceptibility to Oxidopamine
Oxidopamine results in increased expression of PARK7 mRNA; Oxidopamine results in increased expression of PARK7 protein
Oxidopamine affects the localization of PARK7 protein
CTD PMID:18377993, PMID:20851755, PMID:21372141, PMID:25129099 NCBI chr 5:167,982,438...168,004,724
Ensembl chr 5:167,982,439...168,004,724
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage
increases activity
ISO
EXP
OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; TH protein inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; tricetin inhibits the reaction [Oxidopamine results in increased expression of PARP1 protein]
Oxidopamine results in increased activity of PARP1 protein
5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in increased activity of PARP1 protein]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]
CTD PMID:10397638, PMID:19815691, PMID:21397656, PMID:25446857, PMID:30707903, PMID:31176653, PMID:31705926 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pdcd10 programmed cell death 10 multiple interactions EXP
ISO
PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]]
[Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 mRNA; [Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 protein; Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]]
CTD PMID:31778666 NCBI chr 2:173,966,701...174,012,730
Ensembl chr 2:173,967,080...174,012,676
JBrowse link
G Pdgfrb platelet derived growth factor receptor beta decreases expression EXP Oxidopamine results in decreased expression of PDGFRB mRNA CTD PMID:15518916 NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
JBrowse link
G Pdhb pyruvate dehydrogenase E1 subunit beta decreases expression ISO Oxidopamine results in decreased expression of PDHB mRNA CTD PMID:19763263 NCBI chr15:18,540,826...18,546,855
Ensembl chr15:18,539,210...18,546,854
JBrowse link
G Pdia3 protein disulfide isomerase family A, member 3 increases expression EXP Oxidopamine results in increased expression of PDIA3 mRNA CTD PMID:12486162 NCBI chr 3:113,376,983...113,400,707
Ensembl chr 3:113,376,983...113,400,707
JBrowse link
G Pdia6 protein disulfide isomerase family A, member 6 increases expression EXP Oxidopamine results in increased expression of PDIA6 mRNA CTD PMID:12486162 NCBI chr 6:42,568,269...42,585,654
Ensembl chr 6:42,568,220...42,585,652
JBrowse link
G Pdyn prodynorphin multiple interactions
increases expression
decreases expression
ISO
EXP
[Levodopa co-treated with Oxidopamine] results in increased expression of PDYN mRNA; [Levodopa co-treated with Oxidopamine] results in increased expression of PDYN protein; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of PDYN mRNA]
Oxidopamine results in increased expression of PDYN mRNA
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; [Levodopa co-treated with Oxidopamine] results in increased expression of PDYN mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of PDYN protein; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; Corticosterone inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; IEM 1460 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of PDYN mRNA]
CTD PMID:7477882, PMID:12127155, PMID:14697317, PMID:15207268, PMID:15610165, PMID:15659429, PMID:16139809, PMID:17219962, PMID:17241287, PMID:17329435, PMID:18687386, PMID:19118628, PMID:19520364, PMID:19660528, PMID:20456008 NCBI chr 3:122,194,327...122,206,671
Ensembl chr 3:122,194,329...122,206,671
JBrowse link
G Penk proenkephalin multiple interactions
increases expression
ISO
EXP
[Oxidopamine co-treated with Levodopa] results in increased expression of PENK mRNA
Oxidopamine results in increased expression of PENK mRNA; Oxidopamine results in increased expression of PENK protein
[Levodopa co-treated with Oxidopamine] results in increased expression of PENK mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of PENK mRNA; [TH co-treated with GCH1] inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]]; Corticosterone inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PENK mRNA]; IEM 1460 inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]]; Isradipine inhibits the reaction [Oxidopamine results in increased expression of PENK mRNA]; Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]; S 33084 inhibits the reaction [[Levodopa co-treated with Oxidopamine] results in increased expression of PENK mRNA]
CTD PMID:3838946, PMID:12127155, PMID:15065221, PMID:15659429, PMID:16139809, PMID:17241287, PMID:17329435, PMID:18687386, PMID:18947822, PMID:19118628, PMID:19660528, PMID:20456008 NCBI chr 5:17,056,412...17,061,762
Ensembl chr 5:17,056,419...17,061,837
JBrowse link
G Pink1 PTEN induced kinase 1 decreases expression
multiple interactions
ISO Oxidopamine results in decreased expression of PINK1 protein
PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of VDAC1 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of PINK1 protein]
CTD PMID:30707903 NCBI chr 5:156,677,146...156,689,258
Ensembl chr 5:156,677,146...156,689,415
JBrowse link
G Pnoc prepronociceptin increases expression
decreases expression
EXP Oxidopamine results in increased expression of PNOC mRNA
Oxidopamine results in decreased expression of PNOC mRNA
CTD PMID:19162046 NCBI chr15:48,805,841...48,833,071
Ensembl chr15:48,805,228...48,833,285
JBrowse link
G Pomc proopiomelanocortin multiple interactions
increases expression
EXP Levodopa promotes the reaction [Oxidopamine results in increased expression of POMC protein] CTD PMID:16325000 NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha decreases expression
multiple interactions
ISO Oxidopamine results in decreased expression of PPARGC1A protein
LY 344864 inhibits the reaction [Oxidopamine results in decreased expression of PPARGC1A protein]
CTD PMID:29057453 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Ppib peptidylprolyl isomerase B increases expression EXP Oxidopamine results in increased expression of PPIB mRNA CTD PMID:12486162 NCBI chr 8:71,719,681...71,725,538
Ensembl chr 8:71,719,563...71,725,562
JBrowse link
G Ppid peptidylprolyl isomerase D multiple interactions
increases expression
EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA] CTD PMID:25129099 NCBI chr 2:178,354,830...178,366,843
Ensembl chr 2:178,354,890...178,366,685
JBrowse link
G Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit 1B multiple interactions ISO
EXP
[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of PPP1R1B protein
[Oxidopamine co-treated with Levodopa] affects the phosphorylation of PPP1R1B protein
CTD PMID:17188499, PMID:17596448 NCBI chr10:86,303,727...86,312,770
Ensembl chr10:86,303,727...86,312,762
JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha multiple interactions
decreases phosphorylation
EXP Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein] CTD PMID:16339297 NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
JBrowse link
G Prkcd protein kinase C, delta multiple interactions
increases response to substance
ISO
EXP
Oxidopamine results in increased cleavage of and results in increased activity of PRKCD protein
PRKCD protein results in increased susceptibility to Oxidopamine
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Oxidopamine results in increased cleavage of and results in increased activity of PRKCD protein]; Oxidopamine results in increased cleavage of and results in increased activity of PRKCD protein
CTD PMID:21846476 NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase decreases reaction
affects expression
decreases expression
multiple interactions
increases expression
ISO
EXP
PRKN protein inhibits the reaction Oxidopamine
Oxidopamine affects the expression of PRKN protein alternative form
Oxidopamine results in decreased expression of PRKN protein
PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]; Tretinoin affects the reaction [Oxidopamine affects the expression of PRKN protein alternative form]
PRKN protein inhibits the reaction [Oxidopamine results in decreased expression of TH protein]
Oxidopamine results in increased expression of PRKN mRNA
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]
CTD PMID:15198987, PMID:16914382, PMID:25129099, PMID:28688199, PMID:30707903 NCBI chr 1:48,880,015...50,069,998 JBrowse link
G Psma2 proteasome 20S subunit alpha 2 increases expression EXP Oxidopamine results in increased expression of PSMA2 mRNA CTD PMID:12486162 NCBI chr17:53,091,937...53,102,324
Ensembl chr17:53,091,933...53,102,342
JBrowse link
G Psmb2 proteasome 20S subunit beta 2 increases expression EXP Oxidopamine results in increased expression of PSMB2 mRNA CTD PMID:12486162 NCBI chr 5:144,702,004...144,734,220
Ensembl chr 5:144,701,949...144,734,257
JBrowse link
G Psmc4 proteasome 26S subunit, ATPase 4 increases expression EXP Oxidopamine results in increased expression of PSMC4 mRNA CTD PMID:12486162 NCBI chr 1:84,978,220...84,986,536
Ensembl chr 1:84,978,206...84,986,581
JBrowse link
G Ptger4 prostaglandin E receptor 4 increases expression ISO Oxidopamine results in increased expression of PTGER4 mRNA CTD PMID:31247335 NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
ISO
EXP
N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in increased expression of PTGS2 protein]
rosiglitazone inhibits the reaction [Oxidopamine results in increased expression of PTGS2 protein]
Oxidopamine results in increased expression of PTGS2 mRNA; Oxidopamine results in increased expression of PTGS2 protein
CTD PMID:17855475, PMID:20851755, PMID:22842585, PMID:31247335 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rasgrp1 RAS guanyl releasing protein 1 multiple interactions EXP [Levodopa co-treated with Oxidopamine] affects the expression of RASGRP1 mRNA; [Levodopa co-treated with Oxidopamine] affects the expression of RASGRP1 protein CTD PMID:19171906 NCBI chr 3:108,984,029...109,044,420
Ensembl chr 3:108,984,029...109,044,420
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
affects localization
increases phosphorylation
increases activity
EXP
ISO
Oxidopamine results in increased localization of and results in increased activity of RELA protein; SN50 peptide inhibits the reaction [Oxidopamine results in increased localization of RELA protein]
N-(1-(4-(5-chloro-2-oxo-2,3-dihydro-1H-benzo(d)imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-naphthamide inhibits the reaction [Oxidopamine affects the localization of RELA protein]
chrysin inhibits the reaction [Oxidopamine results in increased phosphorylation of RELA protein]
Oxidopamine results in increased activity of RELA protein
CTD PMID:17368433, PMID:20851755, PMID:29054324, PMID:31247335 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Ret ret proto-oncogene decreases response to substance ISO RET protein mutant form results in decreased susceptibility to Oxidopamine CTD PMID:19767128 NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372
JBrowse link
G Rps6ka5 ribosomal protein S6 kinase A5 multiple interactions ISO [benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of RPS6KA5 protein; [Oxidopamine co-treated with Levodopa] results in increased expression of RPS6KA5 protein; SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of RPS6KA5 protein]; SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of RPS6KA5 protein] CTD PMID:17596448, PMID:19187092 NCBI chr 6:124,557,892...124,735,787
Ensembl chr 6:124,557,913...124,735,778
JBrowse link
G S100b S100 calcium binding protein B multiple interactions
increases expression
ISO chrysin inhibits the reaction [Oxidopamine results in increased expression of S100B protein] CTD PMID:29054324 NCBI chr20:13,130,633...13,142,856
Ensembl chr20:13,130,636...13,142,856
JBrowse link
G Sec11c SEC11 homolog C, signal peptidase complex subunit increases expression EXP Oxidopamine results in increased expression of SEC11C mRNA CTD PMID:12486162 NCBI chr18:61,490,051...61,506,393
Ensembl chr18:61,490,031...61,506,508
JBrowse link
G Serp1 stress-associated endoplasmic reticulum protein 1 increases expression EXP Oxidopamine results in increased expression of SERP1 mRNA CTD PMID:12486162 NCBI chr 2:148,718,279...148,722,263
Ensembl chr 2:148,718,280...148,722,263
JBrowse link
G Sh3kbp1 SH3 domain-containing kinase-binding protein 1 increases expression ISO Oxidopamine results in increased expression of SH3KBP1 mRNA CTD PMID:18535749 NCBI chr  X:37,790,004...38,196,365
Ensembl chr  X:37,790,586...38,196,204
JBrowse link
G Shh sonic hedgehog signaling molecule multiple interactions EXP SHH protein modified form affects the susceptibility to [Apomorphine co-treated with Oxidopamine]; SHH protein modified form affects the susceptibility to [Dextroamphetamine co-treated with Oxidopamine] CTD PMID:11771942 NCBI chr 4:718,538...727,691
Ensembl chr 4:718,538...727,691
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
ISO puag-haad inhibits the reaction [Oxidopamine results in decreased expression of SIRT1 protein] CTD PMID:18675900 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Slc18a2 solute carrier family 18 member A2 decreases expression ISO Oxidopamine results in decreased expression of SLC18A2 mRNA CTD PMID:17803225 NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148
JBrowse link
G Slc1a2 solute carrier family 1 member 2 multiple interactions EXP [Levodopa co-treated with Oxidopamine] results in increased expression of SLC1A2 mRNA CTD PMID:17329435 NCBI chr 3:92,518,679...92,665,731
Ensembl chr 3:92,640,752...92,665,644
JBrowse link
G Slc1a3 solute carrier family 1 member 3 increases expression EXP Oxidopamine results in increased expression of SLC1A3 mRNA CTD PMID:15518916 NCBI chr 2:57,860,881...57,935,363
Ensembl chr 2:57,860,834...57,935,363
JBrowse link
G Slc40a1 solute carrier family 40 member 1 multiple interactions
decreases expression
ISO
EXP
Oxidopamine promotes the reaction [ACO1 protein results in decreased expression of SLC40A1 mRNA]; Oxidopamine promotes the reaction [IREB2 protein results in decreased expression of SLC40A1 mRNA]
Oxidopamine results in decreased expression of SLC40A1 mRNA; Oxidopamine results in decreased expression of SLC40A1 protein
CTD PMID:19913091 NCBI chr 9:52,819,451...52,830,461
Ensembl chr 9:52,894,365...52,912,293
JBrowse link
G Slc6a3 solute carrier family 6 member 3 decreases expression
increases expression
increases response to substance
EXP Oxidopamine results in decreased expression of SLC6A3 mRNA; Oxidopamine results in decreased expression of SLC6A3 protein
Oxidopamine results in increased expression of SLC6A3 mRNA
SLC6A3 protein results in increased susceptibility to Oxidopamine
CTD PMID:10881039, PMID:15303306, PMID:15518916, PMID:20200117 NCBI chr 1:32,323,011...32,363,983
Ensembl chr 1:32,321,580...32,363,983
JBrowse link
G Slc6a4 solute carrier family 6 member 4 multiple interactions EXP [Oxidopamine co-treated with Levodopa] results in increased expression of SLC6A4 protein CTD PMID:20882603 NCBI chr10:63,153,656...63,188,377
Ensembl chr10:63,153,651...63,176,463
JBrowse link
G Snca synuclein alpha increases expression
increases response to substance
ISO
EXP
Oxidopamine results in increased expression of SNCA mRNA alternative form
Oxidopamine results in increased expression of SNCA protein
SNCA protein mutant form results in increased susceptibility to Oxidopamine
CTD PMID:16297908, PMID:19857570, PMID:22016808 NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions
decreases expression
ISO
EXP
salvin inhibits the reaction [Oxidopamine results in decreased expression of SOD1 protein]
Oxidopamine results in decreased expression of SOD1 mRNA; Oxidopamine results in decreased expression of SOD1 protein
CTD PMID:11730701, PMID:25446857 NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
JBrowse link
G Sod2 superoxide dismutase 2 affects expression EXP Oxidopamine affects the expression of SOD2 mRNA CTD PMID:11730701 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Spp1 secreted phosphoprotein 1 decreases expression EXP Oxidopamine results in decreased expression of SPP1 protein CTD PMID:24486959 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression
ISO
EXP
Oxidopamine promotes the reaction [SQSTM1 protein binds to and results in decreased activity of SQSTM1 protein]
Oxidopamine results in decreased expression of SQSTM1 protein
CTD PMID:26409479, PMID:28802652 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Ssr2 signal sequence receptor subunit 2 increases expression EXP Oxidopamine results in increased expression of SSR2 mRNA CTD PMID:12486162 NCBI chr 2:187,951,316...187,960,067
Ensembl chr 2:187,951,344...187,960,063
JBrowse link
G Ssr4 signal sequence receptor subunit 4 increases expression EXP Oxidopamine results in increased expression of SSR4 mRNA CTD PMID:12486162 NCBI chr  X:156,995,763...156,999,702
Ensembl chr  X:156,995,779...156,999,650
JBrowse link
G Stub1 STIP1 homology and U-box containing protein 1 multiple interactions
increases expression
EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of STUB1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of STUB1 mRNA] CTD PMID:25129099 NCBI chr10:15,197,754...15,200,035
Ensembl chr10:15,197,803...15,200,117
JBrowse link
G Tac1 tachykinin, precursor 1 decreases expression
increases expression
EXP Oxidopamine results in decreased expression of TAC1 mRNA
Oxidopamine results in increased expression of TAC1 mRNA
CTD PMID:15303306, PMID:15610165, PMID:18687386 NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
JBrowse link
G Tfam transcription factor A, mitochondrial multiple interactions
decreases expression
ISO LY 344864 inhibits the reaction [Oxidopamine results in decreased expression of TFAM protein] CTD PMID:29057453 NCBI chr20:18,594,057...18,606,106
Ensembl chr20:18,594,037...18,606,151
JBrowse link
G Th tyrosine hydroxylase affects response to substance
multiple interactions
decreases expression
ISO
EXP
TH protein affects the susceptibility to Oxidopamine
3-methyladenine inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein]; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; [TH co-treated with GCH1] inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]]; Drugs, Chinese Herbal inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in decreased expression of TH mRNA]]; isoquercitrin promotes the reaction [Oxidopamine results in decreased expression of TH mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of TH mRNA]; Levodopa promotes the reaction [Oxidopamine results in decreased expression of TH mRNA]; MDL 201053 inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; rosiglitazone inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of TH mRNA]; salvin inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; Tea inhibits the reaction [Oxidopamine results in decreased expression of TH mRNA]; Tea inhibits the reaction [Oxidopamine results in decreased expression of TH protein]
Oxidopamine results in decreased expression of TH mRNA; Oxidopamine results in decreased expression of TH protein
LY 344864 inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; PRKN protein inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; sulforafan inhibits the reaction [Oxidopamine results in decreased expression of TH protein]
TH protein inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]
CTD PMID:9460767, PMID:11730701, PMID:12585172, PMID:14696016, PMID:15659429, PMID:15703272, PMID:15899244, PMID:16480889, PMID:16914382, PMID:17222394, PMID:17803225, PMID:17933546, PMID:19815691, PMID:20232137, PMID:20623773, PMID:21088802, PMID:22842585, PMID:23518299, PMID:24486959, PMID:25129099, PMID:25446857, PMID:28802652, PMID:29057453 NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
JBrowse link
G Timp2 TIMP metallopeptidase inhibitor 2 decreases expression
decreases response to substance
ISO Oxidopamine results in decreased expression of TIMP2 mRNA; Oxidopamine results in decreased expression of TIMP2 protein
TIMP2 protein results in decreased susceptibility to Oxidopamine
CTD PMID:19883732 NCBI chr10:107,338,465...107,386,072
Ensembl chr10:107,338,465...107,386,072
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
EXP
ISO
Oxidopamine results in increased expression of TNF protein
chrysin inhibits the reaction [Oxidopamine results in increased expression of TNF protein]
rosiglitazone inhibits the reaction [Oxidopamine results in increased expression of TNF protein]
CTD PMID:22842585, PMID:29054324 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf1b TNF receptor superfamily member 1B decreases response to substance ISO TNFRSF1B protein results in decreased susceptibility to Oxidopamine CTD PMID:22110694 NCBI chr 5:163,136,390...163,167,299
Ensembl chr 5:163,136,390...163,167,299
JBrowse link
G Tor1a torsin family 1, member A decreases expression EXP Oxidopamine results in decreased expression of TOR1A protein CTD PMID:16325337 NCBI chr 3:9,800,322...9,807,318
Ensembl chr 3:9,800,322...9,807,328
JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression
EXP SN50 peptide inhibits the reaction [Oxidopamine results in increased expression of TP53 protein] CTD PMID:17368433 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Trh thyrotropin releasing hormone multiple interactions EXP [Levodopa co-treated with Oxidopamine] results in increased expression of TRH mRNA; [Levodopa co-treated with Oxidopamine] results in increased expression of TRH protein CTD PMID:21085660 NCBI chr 4:124,110,716...124,113,242
Ensembl chr 4:124,110,716...124,113,242
JBrowse link
G Ubc ubiquitin C increases expression EXP Oxidopamine results in increased expression of UBC mRNA CTD PMID:12486162 NCBI chr12:36,638,457...36,642,734
Ensembl chr12:36,638,457...36,642,734
JBrowse link
G Ube2d3 ubiquitin-conjugating enzyme E2D 3 increases expression EXP Oxidopamine results in increased expression of UBE2D3 mRNA CTD PMID:12486162 NCBI chr 2:240,626,198...240,655,874
Ensembl chr 2:240,627,436...240,655,246
JBrowse link
G Uchl1 ubiquitin C-terminal hydrolase L1 multiple interactions
increases expression
EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA] CTD PMID:25129099 NCBI chr14:43,133,224...43,143,942
Ensembl chr14:43,133,218...43,143,973
JBrowse link
G Vdac1 voltage-dependent anion channel 1 multiple interactions ISO Oxidopamine results in decreased expression of and results in decreased ubiquitination of VDAC1 protein; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of VDAC1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of and results in decreased ubiquitination of VDAC1 protein] CTD PMID:30707903 NCBI chr10:37,724,915...37,752,827
Ensembl chr10:37,724,915...37,752,826
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19785
    role 19732
      biological role 19732
        molecular messenger 18249
          monoamine molecular messenger 575
            catecholamine 529
              dopamine 356
                (2E)-N-[2-(3,4-dihydroxyphenyl)ethyl]-3-(3,4-dimethoxyphenyl)acrylamide 0
                3-amino-N-[2-(3,4-dihydroxyphenyl)ethyl]propanamide 0
                Arachidonoyl dopamine 0
                N-[2-(3,4-dihydroxyphenyl)ethyl]-9-octadecenamide 0
                N-acetyldopamine 1
                N-oleoyldopamine 2
                N-palmitoyl dopamine 0
                dopamine 3-O-sulfate 0
                dopamine 4-O-sulfate 0
                oxidopamine 183
Path 2
Term Annotations click to browse term
  CHEBI ontology 19785
    subatomic particle 19782
      composite particle 19782
        hadron 19782
          baryon 19782
            nucleon 19782
              atomic nucleus 19782
                atom 19782
                  main group element atom 19670
                    main group molecular entity 19670
                      s-block molecular entity 19428
                        hydrogen molecular entity 19418
                          hydrides 18685
                            inorganic hydride 17409
                              pnictogen hydride 17381
                                nitrogen hydride 17223
                                  azane 16940
                                    ammonia 16939
                                      organic amino compound 16938
                                        aralkylamino compound 896
                                          monoamine 575
                                            monoamine molecular messenger 575
                                              catecholamine 529
                                                dopamine 356
                                                  (2E)-N-[2-(3,4-dihydroxyphenyl)ethyl]-3-(3,4-dimethoxyphenyl)acrylamide 0
                                                  3-amino-N-[2-(3,4-dihydroxyphenyl)ethyl]propanamide 0
                                                  Arachidonoyl dopamine 0
                                                  N-[2-(3,4-dihydroxyphenyl)ethyl]-9-octadecenamide 0
                                                  N-acetyldopamine 1
                                                  N-oleoyldopamine 2
                                                  N-palmitoyl dopamine 0
                                                  dopamine 3-O-sulfate 0
                                                  dopamine 4-O-sulfate 0
                                                  oxidopamine 183
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.